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INDUCED PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL PROGENITOR 
CELLS: PROMOTION OF NEURITOGENESIS AND AXON ELONGATION 
THROUGH NEUROTROPHIN AND CYTOKINE PRODUCTION 
 
Adult bone marrow derived, multipotent mesenchymal stem cells (MSCs) have been shown to 
exhibit support nerve regeneration by secreting neurotrophic factors typically produced by 
Schwann cells. However, MSCs have limited expansion capacity, and therefore have limited 
lifespan and use.  
Induced pluripotent stem cells (iPSCs) can potentially overcome this drawback—iPSCs 
are adult cells reprogrammed with pluripotency factors to become like embryonic stem cells. 
Thus, MSCs may be taken from a patient and reprogrammed into iPSCs, such that their 
expansion capacity is virtually unlimited. After expansion, the iPSCs can be differentiated once 
again into mesenchymally-derived induced mesenchymal progenitor cells (MiMPCs). This 
technology has the potential to yield an almost unlimited supply of MSC-like cells.  
Rachel M. Brick, PhD 
University of Pittsburgh, 2017
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We report here that MiMPCs can be induced to produce neurotrophic factors (NTFs) 
such as brain-derived neurotrophic factor (BDNF) at levels comparable to those produced by 
MSCs. NTF production further increases when MiMPCs are induced in a simulated 
inflammatory environment. MiMPCs are also capable of producing multiple other factors and 
cytokines that have been shown to enhance nerve regeneration, including osteonectin and IL-6.  
Our results show that treatment with conditioned medium derived from MiMPCs and 
MSCs resulted in enhanced neuritogenesis and extension lengths of cultures of chick embryonic 
dorsal root ganglia (DRG). MiMPC/DRG co-cultures grown on 2-dimensional electrospun 
nanofibrous biomaterial scaffolds are also comparable morphologically and physiologically to 
MSC/DRG scaffold co-cultures. In these cultures, neurite length is significantly decreased with 
the introduction of a Jak/STAT inhibitor, suggesting that secreted cytokines from the IL-6 family 
are required for neurite extensions. Complexity of these neurite extensions decreases, but is not 
abolished, when Trk-receptor inhibitors are applied, suggesting the involvement of other non-
traditional neurotrophic factors in the MiMPC secretome in the enhancement of neuritogenesis. 
Taken together, these results strongly suggest that MiMPCs may be a suitable clinical 
replacement for MSCs in nerve regeneration cell therapeutics. Future assessment of this 
therapeutic potential will include testing the efficacy of an MiMPC-seeded nerve conduit to 
repair peripheral nerve injury in an experimental animal model, such as the rat sciatic nerve 
transection model.  
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1.0  INTRODUCTION 
Peripheral nerve damage often accompanies and complicates limb injuries. Proper 
healing of nerve damage can be quite challenging, especially as the success of nerve regeneration 
is dependent upon the rate and quality of axon growth and myelination to bridge the gap across 
the injured area. Regeneration is mediated by Schwann cells, which secrete neurotrophic factors 
and migrate to form Bands of Büngner, a longitudinal tunnel that both guides the regenerating 
neuron towards its target and secretes neurotrophic factors to encourage nerve regrowth. 
However, this process is error-prone, and can often result in formation of painful neuromas [1]. 
Currently, the gold standard treatment for large nerve gaps include autologous nerve graft 
surgery at the sacrifice of other nerves from a donor site, but even the best treatment is limited—
even with multiple surgeries, often times complete motor function is never fully regained, and 
the donor site is at least partially deinnervated [2].  
An alternative to the autologous nerve graft is an autologous Schwann cell transplant to 
the injured site. While this method does not sacrifice a healthy nerve, it still risks damage to the 
nerve at the Schwann cell donor site. The patient thus risks similar donor site morbidities as 
those seen in autologous nerve grafts. Allogeneic Schwann cell transplants have also been 
attempted, but due to the immunogenic nature of Schwann cells, these transplants are quickly 
rejected by the host [3]. Because of these limitations, a more practical approach is needed. To 
answer this need, several studies have shown that bone marrow derived mesenchymal stem cells 
 2 
(MSCs) have the ability to act as Schwann-like cells, given the proper induction environment, 
and can support nerve regeneration by secreting neurotrophic factors (NTFs) [4, 5].  
While neurotrophically induced-MSCs (NI-MSCs) are capable of producing many of the 
same NTFs as Schwann cells, they have finite expansion capacity, and require invasive 
techniques to acquire, e.g., bone marrow aspiration. Induced pluripotent stem cells (iPSCs), 
derived by reprogramming adult somatic cells, including MSCs, that exhibit embryonic stem cell 
(ESC)-like pluripotency, represent a potential cell source that can overcome this drawback as 
iPSCs can grow indefinitely [6]. iPSCs are produced by reprogramming with four transcription 
factors and have a virtually unlimited expansion capacity. We and others have shown that after 
expansion, the iPSCs can be differentiated into MSC-like cells, which we have termed induced 
mesenchymal progenitor cells (MiMPCs). In this manner, this technology has the potential to 
yield an almost unlimited supply of MiMPCs. In this study, we aim to test if these MiMPCs, 
originally derived from MSCs, have the same ability to support neuronal regeneration as the 
parent MSC. With this capacity, MiMPCs may represent a potentially infinitely renewable cell 
source for the support of nerve regeneration and cell therapy. Our results show that MiMPCs can 
secrete neurotrophic factors after neuroinductive treatment and can produce factors to improve 
neurite outgrowth in a chick embryonic dorsal root ganglion (DRG) model. These findings 
suggest that neurotrophically induced-MiMPCs (NI-MiMPCs) may be considered a suitable 
substitute cell type to support nerve growth. 
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1.1 IMPACT AND INCIDENCE OF NERVE INJURY 
Peripheral nerve injuries can result in the loss of sensory function, motor function, or 
both, and is a significant cause of morbidity and disability. Because of the close anatomic 
association between nerves and various subcutaneous tissues (such as blood vessel, bone and 
tendon), nerve injuries commonly accompany a number of limb injuries including dislocated, 
fractured or broken bones. For example, the most common form of upper extremity nerve 
injuries associated with fractures is radial nerve injuries resulting from humeral fractures [7]. 
Nerve injuries can also occur as a side effect of surgery. For example, the saphenous nerve is 
often injured during knee surgeries or autogenous hamstring tendon harvesting during anterior 
cruciate ligament (ACL) reconstruction [8, 9].  Shoulder surgeries can also result in iatrogenic 
damage to the nerve or the brachial plexus, which may then require further surgical treatment. In 
these cases, peripheral nerve repair may be more treatable than brachial plexus damage [10]. 
Surgical nerve injuries frequently result in the formation of a neuroma, although these can also 
occur after a crush or stretch injury. Neuromas form from disorganized nerve growth, typically 
by becoming trapped by scar tissue, or become swollen without any abnormal nerve growth. 
While generally benign (malignant nerve tumors are given other terms), these growths are very 
painful and can still affect functional use of the area by limiting motion and contact.  
These types of injuries can have lasting effects on a patient, both in terms of quality of 
life and socioeconomic burden. Not only are surgical procedures costly, patients may also be 
taken out of the workforce, possibly for life, which incurs a burden upon the population as a 
whole in the form of lost labor production [11]. A Swedish study found that the healthcare cost 
of digital nerve injuries alone averaged slightly less than 3,000 Euros in terms of surgical or 
outpatient care (but came close to 6,000 Euros if tendons were involved). Taking into account 
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the value of lost workforce, the cost per patient could be as high as 9,000 Euros, depending on 
the type of work forfeited. The bulk of patients ranged from 21-40 in age, which makes up the 
primary population of the working force [12]. In the United States, nerve injuries cost the 
healthcare system approximately 150 billion dollars annually. They again occur primarily in 
young, otherwise healthy civilians and military officers who are the most at risk for traumatic 
injuries [13].  
1.2 CLASSIFICATIONS AND TYPES OF NERVE INJURY 
Seddon described in 1943 three classes of nerve injuries—neurapraxia, axonotmesis and 
neurotmesis. In 1951, Sunderland expanded these classifications into five stages.  
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Figure 1. Seddon and Sunderland classifications of peripheral nerve injuries 
Table and schematic diagrams summarizing Seddon’s and Sunderland’s classifications of 
peripheral nerve injuries. 
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1.2.1 Neuropraxia 
Neuropraxia (Sunderland’s Stage I) is caused by a mild neural lesion in the myelin 
sheath, which temporarily blocks nerve conduction [14-16]. The axon is not transected in these 
types of injuries and there is no degeneration of nerve fibers and no interruption in the 
surrounding connective tissues. However, if neuropraxia is caused by mechanical forces (as 
opposed to ischemia), localized degradation of the myelin sheath may occur. It is possible to 
fully recover from this type of injury without surgical intervention in as little as 1 day, or as long 
as 3 months when the myelin sheath is reestablished [15]. 
1.2.2 Axonotmesis 
Axonotmesis (Sunderland’s Stage II) occurs when the axon is transected, but the surrounding 
connective tissues, particularly the endoneurial tube, remains intact [14]. This type of lesion 
typically occurs as a result of a more severe crush injury than those causing neuropraxia. The 
distal end of the transected axon will degenerate via a process called Wallerian degeneration. As 
the structure of the endoneurial tube has not been compromised, these types of nerve injuries 
have a good prognosis (especially for short distances) because the endoneurial tube can act as a 
natural guide for nerve regrowth [15]. In these cases, motor neuron function is less likely to 
recover than sensory function because motor end-plates do not survive as long as sensory 
neurons following denervation [17]. 
 Stages III and IV of Sunderland’s classifications further expounds upon Seddon’s  
axonotmesis by defining transection of the endoneurial tube, and destruction of nerve fascicle 
components except for the epineurium, respectively [16]. Both stages III and IV may experience 
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intraneural fibrosis, which impedes nerve regeneration, and may lead to neuroma formation as 
the guide for nerve growth is lost [15]. Without repair, functional recovery is poor as growing 
nerves generally become disoriented or are blocked due to fibrotic infiltration. 
1.2.3 Neurotmesis 
Neurotmesis (Sunderland’s Stage V) is the most severe classification of nerve injury, where all 
sections of the nerve (axon, myelin sheath, endoneurium, perineurium and epineurium) are 
injured or completely transected. These commonly result from laceration or ischemic injuries. 
Wallerian degeneration also occurs in this case, but prognosis of functional recovery is poor. 
Surgical repair is necessary in this case, and depending on the length of the nerve gap, an 
autograft may be required. 
1.3 NATURAL WOUND HEALING: CLASSIC ROLES OF SCHWANN CELLS AND 
NEUROTROPHINS 
1.3.1 Wallerian degeneration 
To heal, the nerve must follow a sequence of events, which typically begin 24-48 hours after 
nerve transection: Wallerian degeneration, axon regrowth, and end-target reinnervation [1]. 
Without these three events, effective nerve regeneration may not occur, and the patient may 
experience partial or total loss of motor-sensory function. Following peripheral nerve 
transection, the cell body undergoes a metabolic change and prioritizes the production of 
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structural components needed for cellular repair and axon regeneration, in lieu of 
neurotransmitter production [2]. Intracellular and extracellular stores of calcium activate calpain, 
a protease which degrades the cytoskeleton and begins granular disintegration of the axon. Axon 
degradation precedes further degeneration of other nerve components [18]. Calcium release also 
stimulates Schwann cell proliferation [19], as well as formation of new growth cones in the axon 
[20]. 
As mentioned in the previous section, Wallerian degeneration occurs in Sunderland’s 
Stages III-V, generally after loss of membrane integrity and axon degradation [1]. The myelin 
sheath begins to break down and the axons become disorganized and begin to disintegrate. 
Macrophages and Schwann cells are recruited to the site of injury and begin to clear away myelin 
sheath debris. Only by clearing away the injured myelin sheath are Schwann cells able to 
proliferate and form the bands of Büngner to begin the axon regeneration process.   
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Figure 2. Stages of Wallerian degeneration 
(A) Normal, healthy neuron with an intact axon that has been exposed to traumatic injury. (B) 
Upon injury, macrophages are recruited to the site and clear away the degenerating axon along 
with myelin sheath debris. The nucleus is displaced to the periphery of the neuron, along with 
disintegration of Nissl bodies during a process called chromatolysis. (C) Schwann cells 
proliferate to form the Bands of Büngner, engulfing the growing axon. Deinnervated target organ 
begins to atrophy. (D) A successfully regenerated axon reinnervates target organ. (E) Axon 
growth is disorganized and a neuroma forms. End target remains atrophied due to continued 
deinnervation, and loss of sensory or motor function may occur. 
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1.3.2 Schwann cells 
In the peripheral nervous system, Schwann cells take on two forms: myelinating and non-
myelinating. Myelinating Schwann cells wrap around the axon of the nerve to form an insulating 
myelin sheath, allowing for quicker conduction of nerve impulses. Non-myelinating Schwann 
cells wrap around smaller-diameter, C-fiber axons to form Remak bundles [21]. While non-
myelinating Schwann cells do not provide insulation in the same sense that myelinating sheaths 
do, they organize the C-fiber axons by surrounding and separating each axon with cytoplasm 
[22]. Both are responsible for maintaining the health and survival, and promoting the 
regeneration of peripheral neurons.  
When Schwann cells proliferate to form the bands of Büngner, they provide the basal 
lamina structure that will ideally guide the nerve towards the appropriate end-organ. Expression 
of other adhesion molecules, such as N-cadherins and other cadherins, or integrins are increased 
in the bands of Büngner. Some evidence suggests that the type of adhesion molecule expressed is 
dependent upon the type of axon (i.e., sensory or motor) that is regenerating, and that these 
adhesion molecules may help to organize axons and Schwann cells [20, 23]. In addition to 
physical support, they also secrete neurotrophins to encourage nerve survival and growth. It is 
toward these neurotrophins, and other classes of factors, that the growth cone end of the 
regenerating axon is attracted. The growth cone, which is an exploratory apparatus, can also 
respond to other molecules such as neurite-promoting factors (i.e., fibronectin and laminin) and 
matrix precursors (i.e., fibrinogen) [2].  
 11 
1.3.3 Nerve growth factor 
Nerve growth factor (NGF) is often considered the original neurotrophic factor as it was the first 
to be described [24]. It regulates the survival and maturation of developing peripheral nerves, 
particularly sensory and sympathetic nerves. In addition to trophic effects, such as survival and 
maintenance, it has also been demonstrated that NGF has chemotropic properties in that it can 
guide axon growth and promote branching and arborization [2, 25]. Because of these properties, 
many studies have investigated the possibility of applying NGF to nerve lesions in hopes of 
improving healing after nerve lesion [26-28]. These studies showed that when NGF was 
incorporated into constructs such as a fibrin glue [28], fibrin matrices [29], or a heparin-binding 
affinity-based delivery system [30], nerve regeneration across a gap defect was enhanced. Fiber 
count and density increased in the presence of NGF, and improved regeneration efficiency 
compared to controls, even when the nerve defect distance exceeded critical gap length (>15mm) 
[30].  
However, while NGF has certainly proven to enhance nerve regeneration, other 
neurotrophic factors such as brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), 
ciliary neurotrophic factor (CNTF), and glial-derived neurotrophic factor (GDNF) have also 
shown that they are capable of enhancing nerve regeneration and even act synergistically with 
extracellular matrix molecules, with Schwann cells, and with each other [31-34].  
1.3.4 Brain-derived neurotrophic factor 
BDNF has been shown to increase myelin formation [35], and restore motor function and nerve 
conduction velocity to crushed sciatic nerves in rats [36]. Wilhelm, et al showed that both BDNF 
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and Schwann cells had to be present for effective healing of cut peripheral nerves [34]. Increased 
levels of BDNF after injury can also indirectly activate the Jak/STAT pathway in Schwann cells 
by phosphorylating STAT3/STAT1, leading to increased Schwann cell cytokine production that 
promote neuritogenesis and nerve regeneration [37]. Bella, et al, also showed that BDNF can act 
directly on pelvic ganglion in rats, activating the Jak/STAT pathway to promote neurite growth, 
an effect which could be truncated with the application of Jak/STAT inhibitor AG490 [38]. 
Ataxic mice injected intrathecally with BDNF-producing mesenchymal stem cells also showed 
lowered apoptotic markers and decreased degeneration of axons, demonstrating the clinical 
potential for BDNF-producing stem cells not only in post-injury applications, but in 
neurodegenerative diseases as well [39].   
1.3.5 Glial cell line-derived neurotrophic factor 
GDNF promotes the survival of both sensory and motor neurons, and, like NGF, was also 
capable of increasing nerve fiber density and myelination. A 2006 study by Li, et al showed that 
when Schwann cells overexpressing GDNF was introduced at the site of injury in rat sciatic 
nerve, there was an increase in survival and function of motor neurons. Nerve regeneration was 
also improved over controls when conduits filled with GDNF-expressing Schwann cells were 
used to bridge a transection gap [40]. Unlike NGF, nerve injuries treated with GDNF regrew 
nerves with larger diameters, which indicated that GDNF was more capable of promoting nerve 
maturation [41]. Of particular importance is the role of GDNF in delayed nerve repair. If surgical 
repair is not possible immediately after nerve injury, chronic axotomy may occur where neurons 
are no longer able to innervate their end-target organs, which yields a high probability of poor 
nerve regeneration. However, a study by Wood et al showed that an implantable, slow-release 
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GDNF delivery system via microspheres can still enhance motor nerve regeneration even after 
nerve repair was delayed for 1 week [42]. 
1.3.6 Neurotrophin-3 
A study focusing on neurotrophin-3 (NT-3) showed that when rats with dorsal root ganglia 
(DRG) avulsions were given intrathecal NT-3, they were able to regenerate the DRG through the 
dorsal root entry zone into the spinal cord, which promoted functional recovery [43]. NT-3 has 
also shown to be effective in improving both weight and functional use of muscle fibers 
containing heavy myosin, implying that NT-3 is not only capable of improving motor neuron 
deficits, it may potentially prevent atrophy of the type 2b subset of muscles fibers [44].  
1.3.7 Ciliary neurotrophic factor 
Similarly, CNTF administration to a sciatic nerve injury also promoted higher functional motor 
recovery as well as conservation of muscle mass when compared to NGF administration alone 
[45], indicating that aside from survival-promoting effects, CNTF also plays a role in survival 
and regeneration of motor neurons [46]. Unlike other neurotrophic factors, CNTF does not seem 
to be involved in neuronal survival, but rather only exerts its effects after nerve injury. This 
hypothesis is supported by the fact that newborn animals do not express CNTF, but if exogenous 
CNTF is introduced, motoneurons, which are highly susceptible to retrograde cell death 
following axotomy, are protected from degeneration [47]. In a progressive motor neuronopathy 
(pmn) mouse, the mutation causes disease and degeneration of motor neurons, resulting in death 
by the seventh or eighth week. However, Sendtner et al found that creating a lesion in the facial 
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nerves dramatically decreased the level of degenerated motor nerves due to endogenous release 
of CNTF by Schwann cells after injury. In pmn mice lacking endogenous CNTF, this protective 
effect was not seen [48].  
 
Table 1. Neurotrophins and their receptors and functions 
1.4 ROLE OF INFLAMMATION AND OTHER NON-NEUROTROPHINS 
1.4.1 The IL-6 cytokine superfamily 
Aside from the classically studied neurotrophins, the roles of other cytokines (particularly those 
in the IL-6 cytokine superfamily) and growth factors in peripheral nerve injury have come to 
light. As LIF and CNTF are both part of the IL-6 cytokine superfamily, these two molecules 
share very similar actions on sensory neurons. These molecules were originally termed 
 Receptors Function 
Nerve growth factor (NGF) Trk-A (high affinity); 
p75/NGFR (low affinity) 
Guides axon growth; regulates 
nerve maintenance, survival and 
proliferation; promotes branching 
and arborization 
Brain-derived neurotrophic 
factor (BDNF) 
Trk-B (high affinity); 
p75/NGFR (low affinity) 
Increase myelin formation; promote 
Schwann cell cytokine production; 
enhances neurogenesis and neuron 
sprouting 
Glial-cell derived 
neurotrophic factor 
(GDNF) 
RET; co-receptor GFRα1 Promotes survival of sensory and 
motor neurons; increases nerve fiber 
density; promotes myelination 
Neurotrophin-3 (NT-3) Trk-C (high affinity); TrkB; 
p75/NGFR (low affinity) 
Survival and differentiation of 
neurons; encourages neurogenesis 
and synapse formation 
Ciliary neurotrophic factor 
(CNTF) 
CNTFR; IL6R; co-receptor 
gp130 
Survival and regeneration of motor 
neurons; neuroprotective 
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hematopoietic regulators for their effects on myeloid cells, but have since been identified as 
having a role in cholinergic differentiation [49].  
A number of diverse and seemingly contradictive functions have been found for leukemia 
inhibitory factor (LIF). When acting upon an embryonic stem cell, LIF inhibits differentiation 
and maintains pluripotency. However, in the presence of myeloid leukemic cells, LIF initiates 
terminal differentiation, and it is for this function that the cytokine is named [50]. A study in 
2003 showed that over the span of 4 months, delivery of leukemia inhibitory factor (LIF) to a 1 
cm nerve gap via a conduit significantly enhanced the regenerated axon distance when compared 
to plain nerve conduit controls [51]. Conversely, when LIF was knocked down via LIF-specific 
antisense morpholinos, STAT3 activation was markedly decreased, which resulted in a severe 
impairment in nerve healing and axon sprouting after injury, indicating that LIF signaling plays a 
beneficial role in functional recovery [52]. 
IL-6 is a cytokine widely known for both its pro- and anti-inflammatory properties. 
Among its role in the inflammatory response, studies have demonstrated an extensive variety of 
other functions for IL-6, including enhancing proliferation, maintaining stemness of MSCs, and 
protection from apoptosis [53].  It has been shown to play a positive role in nerve regeneration 
after traumatic nerve injury in vivo and that in the presence of increased IL-6 and overexpression 
of IL-6R, axotomized nerves regenerate quicker than their wild type counterparts [54, 55]. 
Exogenous IL-6, when delivered to the site of injury, can increase expression of growth-
associated genes such as GAP-43 and small proline rich protein 1A (SPRR1A), and can signal 
through the gp130 receptor to activate the Jak/STAT3 pathway to overcome the actions of axonal 
growth-inhibitory myelin proteins [55, 56]. Studies have shown that both Trk and gp130 
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receptors can activate the Jak/STAT3 pathway, which plays an integral role in axon regeneration, 
and the inhibition of which can severely impede axon extension length [37, 57].  
Schwann cells has also been found to produce the extracellular matrix molecule, 
osteonectin, also known as secreted protein acidic and rich in cysteine (SPARC) or BM-40 [58]. 
As the name might suggest, osteonectin was originally discovered as an osteoblast secretion and 
promotes bone formation and initiating mineralization. It does this by binding both collagen I 
and hydroxyapatite crystals, and linking and depositing calcium and phosphate from surrounding 
solution to the non-mineralized matrix tissue [59]. More recently, it has been shown that 
Schwann cells are also capable of secreting osteonectin, and that it may play a synergistic role 
with BDNF [32] and NGF [33] in terms of promoting nerve regeneration and axon elongation. 
These papers showed that when the actions of BDNF and NGF were inhibited via blocking the 
Trk receptors, nerve growth, while lessened, was not abolished. The study found that Schwann 
cell conditioned medium containing osteonectin were able to partially rescue the regeneration of 
nerve axons when Trk receptors were pharmacologically inhibited, but when osteonectin was 
removed from the conditioned medium, nerve regeneration was suppressed [32, 33]. 
 
Table 2. Non-neurotrophins and their receptors and functions 
 
 Receptors Functions 
Interleukin-6 (IL-6) IL6R (CD126); gp130 
coreceptor 
Anti-inflammatory (myokine); 
mediates fever; pro-inflammatory 
(cytokine) 
Leukemia inhibitory factor 
(LIF) 
LIFR (CD118); gp130 
coreceptor 
Inhibits differentiation (embryonic 
stem cells); induces differentiation 
(myeloid leukemic cells) 
Osteonectin Unknown Binds calcium and collagen; cell-
matrix interactions; bone 
mineralization 
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1.5 MODERN SURGICAL REPAIR METHODS 
Timely surgical repair after traumatic nerve injury remains the best treatment method. If the 
nerve is transected, a direct end-to-end repair with no tension placed on the two nerve ends gives 
the best chance for functional recovery. However, when a tensionless, end-to-end repair cannot 
be performed, the current gold standard of repair for nerve injuries with a critical gap is surgical 
nerve autografting, a technique developed around World War II, and in the last 50 years, only 
minute improvements have been made in surgical techniques [13]. 
1.5.1 The nerve autograft 
Typically, in a nerve autograft, characteristics of the nerve must be considered. Diameter, 
patterning and number of fascicles, length required, cross-sectional shape and area, and patient 
preferences must all be taken into consideration [60]. The surgeon will harvest a section of nerve 
from a healthy donor site on the patient’s body that is deemed less vital and graft the donor 
section into the primary site of injury. Some of the more commonly used donor nerve sites 
include the sural nerve or saphenous nerve for upper body injuries. As with direct end-to-end 
repair, there should be no tension placed on host or donor nerve ends, so the harvested donor 
nerve should be approximately 25% longer than the gap distance [60]. The drawback to this 
approach remains the fact that a second site of injury will result from the surgical removal of a 
nerve section, which may risk the donor site suffering from the same morbidities as those seen in 
typical nerve injuries (i.e., neuroma formation, scarring, loss of sensation or function) [61]. 
Though this approach is deemed the gold standard when alternative approaches are 
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contraindicated, only up to 40-63% of patients experience functional recovery with nerve 
autografts depending on time elapsed, and severity and location of injury [60].  
1.5.2 Nerve transfer surgery 
Nerve transfer surgeries remain an alternative option to the autograft. This technique, first 
described by Tuttle in 1913 [62], has been developing over the past decades with reports of 
positive outcomes, particularly in cases of injuries to the upper extremities (upper arm or 
proximal forearm) and brachial plexus reconstruction [63-65]. In these cases, the surgeon will 
opt to use a redundant nerve in close proximity to the injured or avulsed nerve as a donor of 
neurons and axons in order to reinnervate the affected organ [63]. For example, the intercostal 
nerve can be transferred to help repair and reconstruct both sensory and motor brachial plexus 
nerve injuries [64]. Multiple nerve transfers may also be required in certain circumstances. In 
cases where restoration of elbow flexion is necessary, the most commonly performed procedure 
is a double fascicular nerve transfer, where median and ulnar nerves are coapted to the 
musculocutaneous nerve, reinnervating the bicep [63].   
1.6 STEM CELLS IN TISSUE REPAIR 
While various surgical methods yield moderate success in terms of functional recovery, many 
studies have investigated the possibility of applying stem cells from a myriad of sources towards 
nerve regeneration in a cellular therapy approach.  
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1.6.1 Neurotrophic potential 
Among the most common sources of stem cells used were those derived from muscle [5, 66], 
bone marrow [4, 67-70], embryonic, neural and adipose tissues. Of particular interest is the 
ability of these cells to produce neurotrophic factors and act as replacements for Schwann cells 
in the event of traumatic nerve injury. Through exposure to environmental cues, studies have 
shown that cells can be differentiated in vitro toward a more neuro-supportive phenotype that 
enhances the secretion of neurotrophic factors and myelinating ability. This approach commonly 
exposes stem cells to β-mercaptoethanol, all-trans retinoic acid, IBMX, forskolin, and neuregulin 
[5, 68, 71]. While many studies have reported the benefits of differentiating stem cells [70, 72-
74], other studies have shown that undifferentiated stem cells can be equally effective [39, 75]. 
The main appeal of the use of undifferentiated stem cells comes from cutting the time needed for 
cell treatment and differentiation, possibly making this approach more applicable in the clinic 
[76]. Further arguments for using undifferentiated stem cells come from reports stating that 
maintaining differentiation in vivo is difficult once environmental cues are removed, though 
contradictory findings have been published in other studies that show advantages for either 
differentiated or undifferentiated cells, or that there is no significant difference [76]. The findings 
presented in this body of work agree that there does not appear to be a significant difference 
between undifferentiated and differentiated stem cells when it comes to neuritogenesis or axon 
elongation in peripheral nerve regeneration.  
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1.6.2 Traumatized muscle cells 
While traumatized muscle stem cells have been shown to secrete neurotrophic factors and boost 
axon elongation, these cells fit in a rather particular niche of usage, in that they are reasonably 
accessible after blast trauma. This makes muscle stem cells a viable source of cells taken from 
debrided injury zones from musculo-skeletal trauma. Stem cells taken from these injured tissues 
can produce neurotrophic factors such as BDNF, NT-3 and CNTF [77], and are capable of 
enhancing the extension of growing axons [5]. Lavasani, et al showed that the use of non-
traumatized muscle progenitor stem cells also mitigated skeletal muscle atrophy typically found 
with nerve injury [66].  
1.6.3 Mesenchymal stem cells 
Mesenchymal stem cells (MSCs) sport several advantages as a candidate for cellular therapy in 
nerve regeneration. Since their discovery in the 1960s [78], they have been well studied and 
characterized such that we now have defined a minimum criteria for MSCs [79]. The use of these 
cells also carries little ethical implications compared to other sources like embryonic stem cells. 
Studies have shown that MSCs are less immunogenic, particularly by secreting high levels of 
cyclooxygenase-2 (COX2), a T-cell activation inhibitor [214], which lowers the risk of rejection 
in allogeneic transplants [80]. Many studies have shown that MSCs are readily able to produce 
various neurotrophic factors as well as cytokines that have a positive effect on nerve regeneration 
[68, 74]. The combination of the above factors makes them a promising therapy option in the 
short term, and transplantation studies have shown that MSCs, whether injected locally or 
systemically, are capable of enhancing nerve regeneration. For example, Xia et al showed that 
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MSCs introduced through the femoral artery to STZ-induced diabetic rats showed improvement 
in restores neuropathic morphology [207]. Marconi, et al similarly showed that systemically 
injecting adipose-derived MSCs into mice down-regulated inflammation and improved 
functional recovery in acute sciatic nerve crush [75]. Systemically injected MSCs are capable of 
homing in to the lesion site via chemotactic signals, though this approach typically requires a 
large quantity of cells as a substantial portion (90%) of injected cells will collect and form 
emboli in the lungs [213]. Local application of MSCs via scaffolds also requires vast numbers of 
cells, however, MSCs can be difficult to harvest from bone marrow, and their usage and lifetime 
is finite as they senesce after several passages in culture, which may subject the already injured 
patient to further invasive and painful procedures.  
1.6.4 Embryonic stem cells 
Embryonic and pluripotency stem cells are attractive alternatives to the typical sources of adult 
stem cells. Since Thomson described their isolation method in 1998 [81], human embryonic stem 
cells (hESCs) have taken a center stage in regenerative medicine. As these cells can theoretically 
be propagated infinitely, and can potentially be differentiated into any cell type given the 
appropriate environmental cues, many researchers have devised methods to differentiate hESCs 
into MSCs [82, 83] or neural lineage cells [84, 85]. There is great potential for these cells in 
regenerative medicine, but working with them comes with its own set of challenges. hESCs, as 
their name implies, are isolated from embryos at the blastocyst stage of development, a process 
that destroys the embryo. This fact has embroiled the use of hESCs in research in much 
controversy. Differentiated hESCs, when transplanted, risk immune rejection, but a study by 
Rong, et al showed that a knock-in of constitutively expressed CTLA4-Ig/PD-L1 into allogenic 
 22 
hESCs provided a means of localized immune protection without resorting to systemic immune 
suppression [86]. While this approach seems promising, genetic modification of hESCs along 
this particular route is questionable as it opens up the potential for tumorigenic or viral-infected 
hESCs to escape immune detection.  
1.6.5 Induced pluripotent stem cells 
The method to reprogram induced pluripotent stem cells (iPSCs) from mouse fibroblasts was 
first discovered and described by Yamanaka and Takahashi in 2006 [87], for which a Nobel 
Prize was awarded. iPSCs are adult somatic cells, such as fibroblasts, that have been 
reprogrammed to an ESC-like state. The significance of this discovery cannot be overstated, as 
the scientific community now has the potential means to replace the controversial use of human 
embryonic stem cells in research, as well as a versatile tool to develop in vitro disease models for 
any genetic disease from which cells may be obtained from a patient.  
1.6.6 iPSC development  
The traditional Yamanaka iPSC-generation method includes using retrovirus to introduce four 
transcription factors into adult somatic cells: Sox2, Oct3/4, Klf4, and c-Myc. However, as 
retroviral reprogramming relies upon inserting genetic factors into the genome, this process risks 
causing genetic mutation and dysfunction. It is important to note that continued exogenous or 
ectopic expression of these reprogramming factors can lead to dysplastic lesions [88]; it is thus 
critical to optimize the transient expression of these reprogramming factors. Since Yamanaka’s 
initial discovery, other viral methods, including lentivirus and adenovirus [89], have been used to 
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generate iPSCs. Adenovirus is an attractive alternative to retrovirus because their use can induce 
transient exogenous expression of genes without integration into the genome [90]. Recently, 
some studies have focused on alternative, non-viral methods to generate iPSCs. These include 
plasma transfections, and the use of the Piggybac transposon system [91]. Nuclear transfer has 
also been used to generate iPSCs from mouse fibroblasts [92], as well as transfection with multi-
protein expression vectors [93]. There have been multiple reports that small molecules such as 
GSK3-β inhibitor and ascorbic acid [94], can increase reprogramming efficiency by acting as 
replacements for c-Myc (GSK3-β inhibitor CHIR99021) or Klf4 (GSK3-β inhibitor kenpaullone) 
[95, 96].  
1.6.7 iPSC characteristics 
To be considered an iPSC, the generated cell must maintain several characteristics. They must be 
positive for expression of pluripotency stem cell markers such as Sox2, Oct3/4, SSEA3, SSEA4, 
TRA1-60 and TRA1-81 [91]. Histological staining of cells implanted into NOD/SCID mice must 
show the formation of all three germ layers (mesenchymal, ectodermal and endodermal) in the 
gold standard teratoma assay in order to establish the pluripotency of the generated cells [97]. 
Germline competence can be achieved with selection for Nanog expression, as Nanog is highly 
associated with pluripotency, and is a target of Oct3/4 and Sox2. Subsequently, these Nanog-
expressing iPSCs can integrate into embryos and contribute to form adult chimeras [90].  
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1.6.8 iPSC differentiation potential 
As iPSCs can theoretically be differentiated into any cell type, given the appropriate 
environment, they are an attractive alternative to embryonic stem cells as they pose much less of 
an ethical quandary. Our laboratory has explored the use of iPSCs as a possible replacement for 
MSCs in terms of differentiation potential, proliferation rate, and phenotypic similarity. Our 
study found that while MSC-parentage induced iPSC-derived mesenchymal progenitor cells 
(MiMPCs) were a distinct population of cells regarding expression patterns of mesenchymal and 
pluripotency genes, they exhibited the morphologies typical of MSCs and fibroblasts, and were 
still capable of osteo-, adipo-, and chondrogenesis [98].  
iPSCs have also been explored as a method to model nerve cultures, particularly 
Schwann cell cultures. Schwann cells and neurons are difficult to isolate and culture, but as 
iPSCs can be differentiated into both neurons and Schwann cells [99, 100], these cells may offer 
a new way for researchers to study nerve regeneration and translational medicine. These cells 
have the potential to be powerful research tools in regenerative medicine once reliable, standard 
differentiation protocols are established.  
1.6.9 Key differences between MSCs and iPSC-derived MSC-like cells 
Recently, mesenchymal-like cells have been differentiated from iPSCs in our laboratory, termed 
induced mesenchymal progenitor cells (iMPCs)[98]. iMPCs were characterized in terms of their 
likeness to MSCs, especially concerning similarities in cell surface markers and ability to 
differentiate along adipogenic, osteogenic, and chondrogenic lineages. Several cell types were 
examined—iMPCs differentiated from iPSCs reprogrammed from amniotic epithelial cells, and 
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from mesenchymal cells, termed AE-iMPCs and M-iMPCs repectively. As there is currently no 
standard protocol to differentiate human embryonic cells or iPSCs into mesenchymal-like cells, 
in addition to various cell types, different methods were used to differentiate iPSCs into iMPCs. 
Diederichs confirmed that iMPCs shared a similar morphology as those seen in MSCs and 
fibroblasts, and demonstrated that iMPCs expressed many of the same cell surface markers 
including CD73, CD44 and CD105.  
As previously stated, there is no standardized protocol to differentiate iPSCs into iMPCs, 
resulting in difficult and varied characterization of the iMPC cell type. Diederichs, et al, 
examined which method would yield an iMPCs that would most closely resemble the well-
defined MSC. Various methods were used to differentiate iPSCs into iMPCs, including embryoid 
body generation, spontaneous differentiation, indirect coculture with MSCs, and treatment with 
unconditioned MSC growth medium [98]. 
However, there were key differences that made iMPCs a distinct cell type from MSCs. 
While iMPCs were capable of limited differentiation, indicating that they were indeed MSC-like, 
there were fundamental differences at the gene expression level regarding in vitro trilineage 
differentiation. MSCs also out-performed iMPCs in terms of differentiation, and as iMPCs were 
only partially able to differentiate in vitro, the authors concluded that iMPC cultures actually 
form heterogeneous populations. However, iMPCs were capable of inducing ectopic bone 
formation in vivo, demonstrating again that a subset of the iMPC population are MSC-like. The 
authors state that iMPCs are an attractive MSC-like cell type, though their utility may be limited 
until they can be enriched to form a more homogenous population of truly MSC-like cells [98]. 
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1.7 SYNTHETIC AND NATURAL SCAFFOLDS 
Multiple studies have shown that topographical cues can affect adhesion, growth and 
differentiation of various cell types. For example, Embryonic stem cells can also be cultured on 
nanotopographical surfaces, and under these conditions, can be differentiated along 
mesenchymal lineages without the typical chemical induction treatments [82]. MSCs cultured on 
TGF-β1-loaded aligned electrospun nanofibrous scaffolds were more apt to differentiate toward 
myogenic lineages than MSCs grown on tissue culture polystyrene with TGFβ1-supplemented 
medium [101]. Yim et al. also found that when MSCs were given a nanotopographical surface 
along with biochemical cues, neural markers were significantly upregulated compared to when 
MSCs were cultured with biochemical cues alone [102]. Neurons too, can sense and respond to 
nanostructures, which ultimately affect adhesion, viability and axon pathfinding [103, 104]. 
Studies have found that in addition to directional guidance, these topographical structures can 
also decrease the number of neurites and branching [105, 106] and increase the length of neurite 
extensions [107, 108]. As important as it is for nerves to receive biochemical support, it is of 
equal importance to provide a physical guide so regenerating axons do not lose their way to the 
end target. The longer the distance required of the neuron to regenerate, the more likely a 
neuroma will form due to disorientation of extending neurites.  
Various materials have been investigated for their potential usage in biological scaffold 
nerve guides. Natural polymers and extracellular matrix scaffolds have been constructed from 
collagen, hyaluronic acid, agarose, chitosan and fibrin gels. However, as these materials do not 
afford the mechanistic strength needed, or degrade too quickly, they are often combined with 
synthetic polymers to improve these qualities [109, 110]. Commonly used synthetic polymers 
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include poly-l-lactic acid (PLLA), poly-caprolactone (PCL), poly-lactic-co-glycolic acid (PLGA) 
and polyglycolic acid (PGA) [222]. 
1.7.1 FDA regulatory requirements 
The first generation of synthetic nerve scaffolds were generally made of silicone which, while 
inert, were nonresorbable and often caused compression injury to nerves. They also required a 
secondary surgery for removal [111]. Today, to be considered a candidate for use as a nerve 
growth conduit, the FDA has required that nerve growth conduits be able to provide mechanistic 
support to regrowing axons, as well as prevent fibroblastic infiltrates, retain any secreted 
neurotrophic factors by nerve ends and Schwann cells, but remain permeable enough to allow for 
the efflux of waste and influx of nutrients and sufficient oxygen [112]. These requirements mean 
that the ideal pore size should range from 10-25 μm to allow for diffusion of molecules, but 
disallow the infiltration of fibroblasts and immune cells [113]. The material should ideally be 
flexible enough to accommodate movement of the limb, but still retain its shape so as not to 
cause further damage and compression to the injured nerve [114]. Scaffolds should also be 
biodegradable to eliminate the need for a secondary removal surgery, but should retain structural 
integrity until after the injury has healed.  
1.7.2 Currently available scaffolds 
There are several FDA-approved nerve conduits available on the market today. Many of these 
scaffolds are constructed from Type I collagen, PGA and PCL. In 2001, the first two collagen 
type I nerve conduits, NeuroMatrix and NeuroFlex, were approved for use by the FDA. Both 
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conduits are flexible and fully resorbable in 4-8 months in vivo. Nutrient perfusion is made 
possible by pores in the 0.1-0.5um range [115]. They are ideal for bridging gaps shorter than 2.5 
cm. In 2004, another collagen type I conduit was approved, NeuraWrap. This conduit was 
designed to prevent neuroma formation and avoid compression of the nerve, with longitudinal 
slits that would provide more yield and minimize encapsulation and entrapment. According to 
the manufacturer, the porous outer membrane would offer mechanical resistance to compression 
by surrounding tissues [115]. NeuroMend is another collagen type I conduit that is similar to the 
others in that a semipermeable membrane allows the passage of nutrients while preventing 
infiltration from fibroblasts and inflammatory cells, but is unique in that it can be unrolled and 
curled to best fit the dimensions needed for the injured nerve [115].  
 Neurotube and Neurolac, composed of PGA and PLCL, respectively, have also been used 
in the clinic. Neurotube was the first synthetic scaffold to be approved by the FDA in 1999 
[115]. It has had positive findings in the clinic when used in short deficits of 3 cm or less, but 
generally did not seem to yield significant improvements compared to nerve graft controls [116]. 
Use of Neurolac has likewise seen positive results in the clinic, and as this particular conduit is 
transparent, it offers the added advantage of monitoring the placement and suturing of nerve 
endings, as well as allowing examination of whether the conduit has become occluded by a blood 
clot or the like [117].  
 Decellularized natural scaffolds can also be used as a nerve conduit. While full allografts 
and xenografts can induce immune reactions and potential subsequent rejection without the use 
of immunosuppressant drugs, decellularized scaffolds can provide the enhanced regenerative 
properties of basal lamina and extracellular matrix without the immunogenic components [118]. 
Both chemical and physical methods have been applied to decellularize scaffolds. Commonly 
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used physical methods include lyophilization, freezing, pressure, agitation, and sonication to 
disrupt cell membranes, resulting in cell lysis [119]. Chemical methods can be used with or 
without physical treatments. Typically, chemical methods include enzymatic digestion or 
treatment with alkaline or acidic solutions, detergents, and hypotonic or hypertonic solutions. 
 AxoGen’s Avance is a commercially available decellularized scaffold which uses a 
proprietary method with detergents and chondroitinases to strip cells away from the extracellular 
matrix. In the clinic, it has been successful in treating nerve gaps up to 3 cm in length [111]. 
Whitlock, et al, compared the results of Avance and NeuraGen (Type I collagen) in 14 mm gaps 
in the clinic and found that Avance promoted nerve regeneration as much as NeuraGen and 
autografts, and demonstrated no significant differences 12 weeks after implantation [120]. 
Clinical trials also showed that Avance implants of 0.5-30 mm in length were able to restore 
sensation after 9 months [115]. 
1.7.3 Scaffolds as a delivery system for neurotrophins 
Scaffolds can also be used as a delivery system for neurotrophic factors to enhance regeneration. 
Sun, et al created a NGF-collagen-binding-domain fusion protein that could bind to collagen, 
showing that NGF could be concentrated and retained at the site of injury, enhancing peripheral 
nerve repair [121]. Kokai, et al, also developed a PCL scaffold as a means of slow-release and 
diffusion of growth factors and oxygen that was dependent upon parameters such as pore size, 
pore percentage, and wall thickness. They found that thicker walls and higher porosity allowed 
for both higher oxygen diffusion as well as higher rate of growth factor retention [112].  
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1.7.4 Scaffold filler materials and growth substrates 
Gels are a remarkably versatile substrate in which to hold additional supplemental components to 
encourage axon elongation. These gels can typically be incorporated into the lumen of the 
scaffold, so that in addition to the physical support from the scaffold, the lumen filling may also 
provide trophic support. Gels can incorporate molecules such as neurotrophins (NGF, CNTF, 
VEGF, BDNF, NT-3), hyaluronic acid, and ECM proteins (i.e. laminin, collagen, and fibrinogen) 
[215]. Autologous Schwann cells and bone stromal cells have been suspended in Matrigel and 
introduced into the lumen of conduits. Studies of molecule incorporation into gels from Williams 
(fibrin [217]), Madison (collagen [216]), Rosen (collagen [218]), Rich (NGF [219]), Hadlock 
(NGF [220]) and Hobson (VEGF [221]), all showed that incorporating their respective molecules 
into hydrogel or Matrigel and including the gel into the lumen of a scaffold increased axon count 
and myelination, improved sprouting and the rate of axon regrowth, and improved functional 
recovery in animal models [215]. 
1.7.5 In vitro models for peripheral nerve injury 
Human samples of compressed nerve tissue are extremely difficult to come by for peripheral 
nerve studies. What limited quantities are available are generally isolated from the median, ulnar, 
tibial and radial sensory nerves [122]. Animal models therefore have great utility in this field of 
study, providing an avenue for researchers to introduce a nerve injury, then follow up with 
monitored treatment methods. In vitro models can also provide invaluable information as they 
are isolated from extraneous factors and can offer a narrower window of study to develop 
treatment methods and examine the effects of any pharmacological agents. As they are generally 
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free from ethical implications, it is highly desirable to conduct nerve studies in vitro prior to any 
animal studies if possible.  
 Numerous cells and cell lines exist that are commonly used in in vitro nerve cell studies. 
Among these are PC12 cells, neuronal cell line 50B11, primary Schwann cell cultures, and adult 
rat dissociated dorsal root ganglion neurons. Nerve cell lines can be used to study cell signaling, 
the effects of drugs or molecules on cells, changes in cell behaviors as a result of external 
influences, and the compatibility of new biomaterials.  
 PC12 cells are a well-established cell line commonly used in exocytosis and neural 
differentiation studies. They were first isolated from a rat pheochromocytoma, in the adrenal 
medulla, by Greene and Tischer in 1976 [123], and were later developed into a clonal cell line. 
PC12 cells have also been used as a model for their non-malignant counterparts, adrenal 
chromaffin cells, as they exhibit many similar phenotypic properties. Their popularity in research 
is generally because they are easily cultured, and are versatile in pharmacological studies. PC12 
cells have also been useful in the investigation of the mechanism of action of neurotoxins. 
PC-12 cells differentiate in response to NGF into a neuronal phenotype. Upon exposure 
to NGF, they stop proliferating and will extend neural processes in which small vesicles will 
aggregate. A study by Zerby and Ewing demonstrated that while the location of exocytosis 
changed with differentiation and frequency of vesicle release decreased, the levels of 
catecholamine contents did not [124]. Signaling through NGF contributes to neurite outgrowth 
via the MAP kinase/ERK pathways [125], the effects of which could be reversed when MAP 
kinase and ERK inhibitors were used [126]. The state of PC12 differentiation could be assessed 
via levels of axonal growth associated protein 43 (GAP43)—levels of GAP43 increased during 
differentiation, but decreased when inhibitors were introduced into cultures.  
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Studies have shown that upon treatment with dexamethasone, PC12 cells differentiate 
into neuroendocrine chromaffin-like cells. The rate of endocytosis and exocytosis, as well as 
excitability and calcium channel coupling, is dramatically increased when PC12 cells have been 
treated for 5-7 days. This discovery was beneficial in allowing research to be performed on 
single cell modulation of neurotransmitter release, and in seeing the effects of pharmacological 
or toxic agents [127]. 
50B11 neuronal cells are an immortalized line of embryonic rat dorsal root ganglia, 
generated via transfection with SV-40 T antigen [128]. Although limited in lifespan and usage, 
50B11 cells provide an in vitro model for nociceptive neuronal studies. Due to their ease of 
culture and differentiation, they are well suited for high-throughput assays for phenotypic and 
drug screens testing for neurotoxic and neuroprotective agents [129]. In the presence of 
forskolin, they are able to differentiate, form neurite extensions, express neural markers, and 
generate action potentials. However, as 50B11 cells are only able to survive for 72 hours after 
differentiation, they are not used for long-term studies, i.e., in myelination studies which require 
over 10 days in culture [128]. Melli, et al, proposed that while 50B11 cells could be used as a 
starting point in high-throughput assays and screens, primary DRG cultures should be used in 
follow-up validation studies [130].  
The use of Schwann cell lines has also led to many discoveries in nerve signaling 
pathways. Armstrong, et al, determined that laminin activated the NF-κΒ pathway by showing 
increased NF-κB-p65 phosphorylation localized to the nucleus. However, upon inhibition of the 
NF-κB pathway, the benefits of laminin was abolished and neurite extension lengths were 
stunted, showing that the NF-κB signaling pathway plays an integral role in activating the 
neurotrophic potential of Schwann cells [131]. Schwann cells have also been used to determine 
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the origins of neurotrophic factors and neurotransmitters. For example, while it was known that 
gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, was present in the peripheral 
nervous system, it was not always known where GABA was synthesized. Using primary isolates 
of Schwann cells, Magnaghi, et al showed that GABA synthetic mechanisms and enzymes were 
present within the Schwann cell. Additionally, they demonstrated that GABA is synthetized and 
localized in Schwann cells, and that allopregnanolone, a GABA-A receptor modulator, can 
further stimulate GABA production [132].  
Dorsal root ganglia (DRGs) are structures found immediately outside the spinal column, 
in the intervertebral foramina, which are small openings present between each pair of vertebrae. 
They are primarily composed of sensory neurons which serve to innervate peripheral organs. Rat 
and chicken embryonic DRGs are commonly used in primary nerve cultures. As these cells are 
longer lived than 50B11 cells, they are ideal for myelin formation studies. These types of cells 
are ideal for assessing what may happen in vivo in peripheral nerves, as primary cultures are 
typically naïve cells harvested from healthy tissues. However, as harvesting primary nerves (as 
well as Schwann cells) requires the dissection from target organs, it is inevitable that axons will 
be transected, therefore making it virtually impossible to culture uninjured primary nerves or 
Schwann cells. For this reason, these in vitro models may be a good way to evaluate 
physiological response or treatment methods for traumatic injury to peripheral nerves, and may 
provide a great avenue to optimize tissue engineered constructs [133].  
DRG cultures are a promising way to assess survival, visualize neurite extensions and 
branching, and study neuron responses to drugs. When dissociated, DRGs or spinal cords can 
also be used to test responses and behaviors in both sensory and motor neurons. DRGs can also 
be directly co-cultured together with Schwann cells to mimic in vivo conditions where Schwann 
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cells provide myelination for axons. From these cultures, it was demonstrated that Schwann cells 
are capable not only of producing neurotrophic factors, but also various extracellular matrix 
proteins that greatly improve the survival and growth of neurite extensions [133, 134]. While 
direct Schwann/DRG cocultures can provide valuable information regarding the interaction 
between the two cell types, as well as how they may respond to pharmacological agents, the fact 
also remains that isolating Schwann cells requires injury of a healthy nerve, and therefore are 
difficult to obtain and culture in sufficient numbers. Of course, as these cultures are performed in 
vitro, observations in all studies should be further validated with in vivo models. 
  Cells and cell lines have their limitations in that not all behaviors observed in culture 
may be applicable to a living model. For this reason, animal models are also commonly used in 
nerve studies, whether the aim is regeneration or disease modeling and treatment. 
1.7.6 In vivo models of peripheral nerve injury 
A number of injury models in animals are used for in vivo studies related to nerve regeneration, 
including inducing crush injuries, lacerations, and compression. Short and long term injuries 
have been studied, commonly using the rat sciatic nerve. Researchers typically utilize behavioral 
observations, nerve conduction/electromyograms, and histology to evaluate and monitor their 
studies. 
 Nerve banding is ideal for modeling chronic compression injuries, and is a technique 
developed by Susan Mackinnon, a leader in peripheral nerve surgery. It is performed by 
surgically exposing the sciatic nerve and applying constrictive tubing around the nerve to 
compress the diameter. Varying degrees of compression can be applied, allowing for flexibility 
in the study to determine effects of “tight” (diameters of 0.6 and 0.9 mm) or “loose” (diameters 
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of 1.1 and 1.5 mm) compressions. In her paper, Mackinnon discovered that at 1 month, rats with 
0.6 and 0.9 mm compressed sciatic nerve exhibited gross signs of Wallerian degeneration, and at 
3 months, nerve regeneration appeared to have occurred around the tubing [135, 136]. 
Meanwhile, rats in the 1.1 and 1.5 mm compression group showed very little necrosis, though 
some nerve swelling did occur. 
 Mackinnon’s model was frequently used by other researchers. In his study with rats, 
Dellon, et al, showed that this method significantly lowered the amplitude and slowed 
conduction velocity, and that this effect was especially pronounced in diabetic rats, indicating 
that hyperglycemia made nerves particularly prone to compression injuries [137]. Gupta and 
Steward also used Mackinnon’s model to examine the effects of compression on Schwann cells. 
In their studies, they used a tube with an inner diameter of 1.3 mm. In accordance with 
Mackinnon’s observations, Gupta and Steward did not observe Wallerian degeneration with this 
looser compression—however, they did find that this level of compression disrupted the myelin 
sheath and prompted Schwann cell proliferation, particularly at the 2 and 4-week time points. 
Their study supports the hypothesis that Schwann cells can be induced to proliferate given 
mechanical stimuli [138].  
 The effects of ischemia have also been studied via pneumatic balloon compression. 
Rydevick, et al observed that 60-80 mmHg pressure was sufficient to cut off blood flow to the 
nerve. The study also showed that 3-7 days after acute ischemia, induced with 400 mmHg 
pressure over 2 hours, nerves still did not recover normal blood flow, and that the previously 
compressed area received slow or stagnant circulation [139]. The authors concluded that 
compressive injury to blood vessels decreased intraneural microcirculation, and that varying 
degrees of pressure can result in blood flow changes. 
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 One disadvantage of these compression models is the introduction of foreign material 
into the body, which may lead to an inflammatory reaction and confound the results of the study. 
Thus, while these compression models are useful in studying varying degrees of injury, other 
models have been developed that result in a pure nerve lesion.  
 Crush injuries are more serious than compression, and almost always lead to Wallerian 
degeneration. Rat sciatic nerve is widely used to simulate this injury, generally to evaluate pain 
and effect on motor function. Mouse models are also valuable due to the wide variety of 
transgenic lines, which allow for a more detailed examination of the roles of any critical 
molecule in nerve regeneration [140]. Typically, nerve crush injuries are simulated via angled 
forceps, chilled forceps, hemostatic forceps and vascular clamps. While this model generally 
does not seem to offer flexibility in degree of injury, this model has proven to be consistent and 
reproducible, making it a valuable model for clinically relevant injuries.  
 Sciatic nerve is not the only nerve used in crush injury models. Burgette, et al describe a 
crush model that uses the intracranial facial nerves in rats [141]. Studies using this model are 
clinically relevant for patients undergoing microsurgery of the skull base for tumors or lesions. 
Disruption of facial nerves can impact the patient both psychologically and socially. While 
developing this model, Burgette used sham surgeries as controls and determined that the surgical 
procedures were safe, and that the only cause of nerve damage was the 1-minute crush to the 
facial nerve. Rats in the crush injury group exhibited complete facial paralysis, which included 
loss of blinking reflex and lack of whisker movement [141].   
 Partial or full nerve transections have also been utilized as a model for nerve injury and 
pain. This has served as a great model for examining the efficacy of surgical repair and suturing 
nerve ends, as well as other methods. For example, in Brushart’s initial studies with rats in 1990, 
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he found that motor neurons will preferentially reinnervate a distal motor branch, even if there 
are sensory nerves mixed in, demonstrating a staggered regenerative process, and the presence of 
a mechanism that promotes specificity between sensory and motor nerves. It appeared that initial 
regeneration during the first 2 weeks post-injury, neuron regeneration was random where 
motoneurons projected indiscriminately to sensory and motor neurons. However, in follow up 
time points, the authors noticed a continuous decrease in random projections, where 
motoneurons increasingly matched up with distal motor branches, and collateral sensory axons 
were “pruned” out [142].  
Further studies in by Al-Majed and Brushart, et al, showed that the application of 20 Hz 
of electrical stimulus accelerated the onset of motor axon regeneration, but ultimately did not 
increase the overall rate of regeneration. However, as the electrical impulse gave the 
regenerating axons a push at the beginning, the authors observed that 3 weeks of regeneration 
with an electrical impulse was equivalent to regeneration seen after 5-8 weeks without stimulus 
[143]. 
Repetitive motion models, while difficult and time consuming to perform, can provide an 
invaluable model for simulating prevalent human conditions that damage nerves such as carpal 
tunnel syndrome. Carpal tunnel syndrome is the most common form of work-related nerve 
inflammation, and causes the highest rate of lost work days, with almost half of all cases 
resulting in 31 days or more of work loss. It is caused by repetitive motion of the wrists and 
hands, leading to compression of the median nerve as it passes through the wrist by flexor 
tendons and interstitial fluid. It is characterized by pain, tingling and paresthesia in the fingers 
and hands, and may extend up the arm. This may lead to muscle weakness and functional 
deficiencies.  
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Cohort studies for carpal tunnel syndrome are time consuming and costly, and difficult to 
control, as repetitive motions may vary from person to person in the workplace or home. There is 
also no method to measure the force exerted or pressure placed on the carpal tunnel by each 
person in the study as they go about their daily activities. This prompted Clark et al to describe a 
repetitive rat model with fully described and controlled repetitive motion. The rats were placed 
into a chamber within a custom designed apparatus and trained to reach outside the chamber to 
pull on a bar for a specified time to obtain food. Over time, the authors measured significant 
decreases in the rats’ grip strength, nerve conduction velocity, and reach rate. Macrophage 
infiltrates and fibrosis increased in and around the medial nerve. From this model, the authors 
concluded that the repetitive tasks were the cause of the exhibited elements of carpal tunnel 
syndrome [144]. 
1.8 HYPOTHESIS AND SPECIFIC AIMS 
Ongoing research suggests that a multitude of stem cell sources can be used to enhance 
peripheral nerve regeneration. While studies have shown that iPSCs can potentially be 
differentiated into functioning nerves themselves, there is little literature on the utility of iPSCs 
promoting nerve regeneration of the patient’s own nerves. Our laboratory has previously studied 
the characteristics of iPSC-derived MSC-like cells, termed MiMPCs, and found that while they 
are a distinct population of cells, they resemble MSCs in terms of cell surface markers and 
trilineage differentiation. Because MiMPCs are derived from iPSCs, they are virtually unlimited 
in terms of availably supply, and represent a unique source of cells for regenerative medicine. 
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However, the therapeutic potential of MiMPCs in traumatic peripheral nerve injury has yet to be 
evaluated.  
The overarching hypothesis is that MiMPCs are capable of neurotrophic activity that can 
be influenced by chemical cues, and provide clinically-relevant enhancements to regeneration of 
peripheral nerves after trauma. The following specific aims were designed to test this hypothesis:  
Specific Aim 1: Determine the optimal line of starting iPSCs and method of 
differentiation to yield the an MSC-like population that closely resembles a nerve lineage 
phenotype, and optimize medium treatment method to elicit the highest neurotrophic potential 
from MiMPCs. 
Specific Aim 2: Determine the components of the MiMPC secretome critical for neurite 
extension branching and length via use of key signaling pathway inhibitors. 
Specific Aim 3: Develop a nerve guide that incorporates the benefits of MiMPCs, either 
with conditioned medium or with cell co-culture.  
The following chapters feature a detailed account of results for each specific aim. 
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2.0  MESENCHYMALLY-DERIVED INDUCED MESENCHYMAL PROGENITOR 
CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS MAINTAIN 
APPROPRIATE NEURAL MARKERS AND SECRETOME 
2.1 INTRODUCTION 
Using the technology described by Yamanaka and Takahashi in 2006, where mouse fibroblasts 
were reprogrammed using transcription factors KLF4, Oct3/4, Sox2 and c-Myc, any adult 
somatic cell can theoretically be induced into a pluripotent stem cell (iPSC) state, mimicking the 
utility of the human embryonic stem cell (hESC). Like the hESC, iPSCs can be differentiated 
into any cell type, given the appropriate environmental cues. The advantage of iPSCs in research 
lies in 1) their relative ease of acquisition, 2) the fact that they are not derived from embryos 
entails significantly fewer ethical implications in their use and 3) that in vitro modeling of human 
cells no longer required invasive procedures to acquire a particular cell type.  
Mesenchymally-derived induced mesenchymal progenitor cells (MiMPCs) can 
potentially be indefinitely differentiated from iPSCs. Their similarities to the well-defined 
mesenchymal stem cell (MSC) make them an attractive alternative, as MSCs may require 
invasive procedures to acquire and isolate, such as bone marrow aspiration or adipose tissue 
biopsies.  
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Previous work in the laboratory has shown that MiMPCs are a heterogeneous population 
that contain a subpopulation positive for typical MSC markers CD105, CD73 and CD44, and 
negative for pluripotent markers CD45, TRA-1-60, and HLA-D/R (human leukocyte antigen-
antigen D related). While capable to a lesser extent than MSCs of chondrogenic, adipogenic, and 
osteogenic trilineage differentiation, their neurotrophic potential has yet to be evaluated.  
Epigenetic memory inherent in iPSCs is a fundamental difference between iPSCs and 
hESCs. This phenomenon can influence gene expression via DNA methylation, a process that 
results in the epigenetic modification of DNA in somatic cells. Residual DNA methylation can 
remain even after reprogramming. The possibility of epigenetic memory playing a role was taken 
into consideration during this previous characterization work. Deiderich’s study was designed 
using iPSCs derived from amniotic epithelial cells (AEiPSCs) similarly differentiated toward 
induced mesenchymal progenitor cells (AEiMPCS) as controls. The results showed no 
significant difference between MiMPCs and AEiMPCs, indicating that epigenetic memory did 
not play a role as far as MSC-likeness.  
As no previous work had been done with MiMPCs in a nerve regenerative capacity, the 
question remained if the source of the parental cell for the iPSCs was critical for performance in 
a neurotrophin supportive manner. The results presented below showed that MiMPCs 
differentiated from iPSCs derived from MSCs were much more adept than AEiMPCs at 
producing BDNF, and thus, we selected MiMPCs for further characterization in terms of 
neuroinduction and comparison to Schwann cells. 
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2.2 METHODS 
2.2.1 Culturing feeder-free induced pluripotent stem cells (iPSCs) in mTeSR medium 
Two lines of induced pluripotent stem cells (iPSC) were piloted in this study—the first were 
reprogrammed from human amniotic epithelial cells, and was a generous gift from Dr. Gerald 
Schatten’s laboratory at the University of Pittsburgh. The second iPSC line tested was 
reprogrammed via lentivirus from human bone marrow mesenchymal stem cells (MSCs) by 
University of Pittsburgh’s Stem Cell Core.  
Preparing iPSC culture substrate. Feeder-free iPSC were cultured on Matrigel coated 
6-well tissue culture plates (all from Corning Incorporated, Corning, NY). Plates were coated 
only 1 day prior to, or immediately before use and never allowed to dry. To coat the plates, 
Matrigel was thawed on ice before use. The tube containing Matrigel aliquot remained sterile 
and stayed on ice for the duration of the coating process. A tube of sterile DMEM (Thermofisher, 
Waltham, MA) was cooled on ice. Once thawed, Matrigel was mixed into the cold DMEM at a 
concentration of 11.6 µl of Matrigel per 1 ml of DMEM. 1 ml of Matrigel/DMEM mix was used 
per well to coat wells in a 6-well plate. The Matrigel/DMEM mix was allowed to coat the plate 
for 1-2 hours at room temperature, or overnight at 4˚C. Prior to seeding cells, Matrigel/DMEM 
coating mix was aspirated and immediately replaced with warmed mTeSR medium (Stemcell 
Technologies, Vancouver, Canada).  
Thawing and culturing iPSCs. iPSCs were thawed, washed with DMEM, centrifuged at 
1.0g for 5 minutes, and gently pipetted with large-bore pipette tips for tissue culture. One vial of 
frozen cells was thawed and plated per well for a 6-well plate. Culture medium used was 
mTeSR1 (Stemcell Technologies), which was prepared according to manufacturer’s instructions 
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and supplemented with 1x penicillin-streptomycin/fungizome (PSF; Thermofisher), and changed 
daily.  
Undifferentiated iPSC culture maintenance. Even with all precautions taken, 
spontaneous differentiation of iPSCs can still occur, determined by morphological changes. 
Undifferentiated iPSCs are typically small in size and grow in tight-knit colonies with a clearly 
defined edge. Once differentiated, cells generally appear enlarged and spread out across the 
culture growth surface. To maintain an undifferentiated iPSC population in culture, these cells 
must be removed via manual dissection under a microscope in sterile conditions. A sterile, 
flame-drawn glass Pasteur pipette was used as a tool for manual removal of these cells.  
Passaging iPSC cultures. Confluence of iPSC colonies was determined by 
morphological observation with phase contrast microscopy using an Olympus CKX41 
microscope (Olympus Corporation, Shinjuku, Tokyo, Japan). As iPSCs did not grow in 
monolayer, the size and apparent depth of the colony was used to gauge confluency. Colonies 
were deemed confluent when the centers of the colony became more refractive, taking on a 
brighter, “shiny” appearance under the microscope, indicating a change in depth, and thus, a 
change in the thickness of the colony. iPSCs were passaged enzymatically, with 1 mg/ml Dispase 
(Stemcell Technologies) for 7 minutes at 37° C. 
iPSCs must be washed with 1x phosphate buffered saline (PBS; ThermoFisher) before 
Dispase could be applied. 1 ml of Dispase was added per well in a 6-well plate and allowed to 
incubate at 37˚C for 7 minutes. After gently washing with 1xPBS, mTeSR medium was added to 
the well and a cell lifter (Corning Incorporated) was used to scrape colonies into suspension. 
Cells were pipetted gently with large-bore pipette to break up colonies and centrifuged at 1 g for 
5 minutes before evenly distributed into fresh Matrigel-coated wells. 
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2.2.2 Differentiation of amniotic epithelial- and mesenchymal- parentage iPSCs 
Two different methods of iPSC differentiation were used: embryoid body (EB) formation, or 
treatment with mesenchymal growth medium (MGM).  
 To form embryoid bodies, iPSCs were first grown to confluent colonies in mTeSR 
medium (Stemcell Technologies) supplemented with 1x penicillin-streptomycin-fungizone (PSF; 
ThermoFisher). Once confluent, colonies were enzymatically digested with 1 mg/ml Dispase 
(Stemcell Technologies) for 7 minutes at 37°C. Cells were then washed with 1x PBS 
(ThermoFisher), and manually scraped off the plate with a cell lifter (Corning Incorporated, 
Corning, NY). Aggregated cell colonies were placed into suspension culture in non-tissue culture 
treated plates (Corning Incorporated) and cultured with EB medium (Dulbecco’s modified 
Eagle’s medium [DMEM], 20% KnockOut serum replacement, 2 mM L-glutamine, 1x MEM 
non-essential amino acid solution [all from ThermoFisher], and 0.1 mM β-mercaptoethanol 
[BME; Sigma-Aldrich, St. Louis, MO]).  
Six-well plates are coated with gelatin (Stemcell Technologies) for 20 minutes. EBs were 
grown for 3 days, then collected and transferred to the gelatin-coated plates with MSC-
differentiation medium (DMEM, 10% fetal bovine serum [FBS; ThermoFisher], 2 mM L-
glutamine, 1 µM all-trans retinoic acid [RA; Sigma-Aldrich], and 1x PSF) for another 8 days. 
After 8 days, EB outgrowths were trypsinized and filtered through a 40 µm mesh. Cells were 
collected and plated onto gelatin-coated tissue culture plastic (TCP) with DMEM and 5% FBS, 
and incubated at 37° C for 1 hour. Cells were washed twice with 1x PBS and the remaining 
adherent cells were cultured in normal MSC growth medium (αMEM, 10% FBS, 1x PSF [all 
from ThermoFisher], and 1 ng/ml basic fibroblast growth factor [FGF2; RayBiotech, Norcross, 
GA]).  
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Treatment with mesenchymal growth medium (MGM) was as follows: when iPSC 
cultures were confluent and ready for differentiation, mTeSR medium was aspirated, cells were 
washed with 1xPBS, and then medium was replaced with fresh mesenchymal stem cell (MSC) 
growth medium (minimum essential medium α [α-MEM; ThermoFisher], 10% FBS, 1 ng/ml 
FGF2, 1xPSF). They were incubated for 7 days with one intermittent medium change. MiMPCs 
were trypsinized and seeded onto gelatin-coated flasks. Cells were passaged and expanded 
following conventional methods for MSCs.  
2.2.3 Neuroinductive treatment of MiMPCs and MSCs 
MiMPCs and control MSCs were plated at approximately 3,000 cells/cm2 on gelatin-coated 
flasks and maintained in MSC GM until the cultures reached 70% confluency. To develop 
optimal neuroinductive treatment of MiMPCs and MSCs, three different protocols were 
assessed.  
Each of the following treatment protocols was preceded by this pre-treatment method: 
For the first 24 hours of the neurotrophic induction, cells were cultured with αMEM 
supplemented with 10% FBS, 1x PSF (all from ThermoFisher), and 1 mM β-mercaptoethanol 
(BME; Sigma-Aldrich). The following 48 hours of pre-treatment included all of the 
aforementioned reagents, and 35 ng/ml retinoic acid (RA; Sigma-Aldrich). 
For 7 days following pre-treatment, MiMPCs and control MSCs were treated with 
neurotrophic induction medium (NIM), consisting of Dulbecco’s MEM (DMEM)/Ham’s F-12 
medium (ThermoFisher) supplemented with 5% FBS, 0.5 mM 3-isobutyl-1-methylxanthine 
(IBMX; Sigma-Aldrich), 10 uM forskolin (Sigma-Aldrich), 20 ng/ml epidermal growth factor 
(EGF; Peprotech, Rocky Hill, NJ), 5 ng/ml platelet derived growth factor (PDGF; Peprotech), 50 
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ng/ml recombinant human neuregulin-beta 1/heregulin 1-beta EGF domain (hNRG1; R&D 
Systems, Minneapolis, MN), 10 ng/ml FGF2, 6 μg/ml RA, 10 ng/ml IL-1β and 2% v/v B-27 
Supplement (ThermoFisher). The MiMPCs and MSCs remained in NIM medium for 7 days, 
with one intermittent medium change after 3 days in culture  
 
Table 3. Neuroinductive medium treatment protocol 
 
Name Steps Reagents 
Pre-treatment 24 hours αMEM, 10% FBS, 1mM BME, PSF 
48 hours αMEM, 10% FBS, 1mM BME, PSF, 35 ng/ml RA 
NIM Days 0-3 
Days 4-7 
DMEM/F12, 5% FBS, PSF, 0.5 mM IBMX, 10 uM forskolin 20 
ng/ml EGF, 5 ng/ml PDGF, 50 ng/ml hNRG1, 10 ng/ml FGF2,  
6 ug/ml RA, 10 ng/ml IL-1β, B-27 supplement 
 
Table 3 illustrates the neurotrophic induction treatment method used here, indicating 
protocol timeline and regents used. Henceforth, all references to NIM will refer to the medium 
described in the above protocol, and all NI- notations will refer to cells that have been treated 
with NIM. All GM- notations will refer to control cells cultured in growth medium that did not 
receive treatment. 
2.2.4 Collecting conditioned medium from MiMPCs and MSCs 
After the 7-day induction in NIM, the MiMPCs and MSCs were cultured in a basal medium 
(DMEM-F12, 5% FBS, insulin-transferrin-selenium-X [ITS-X], pen-strep; all reagents obtained 
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from ThermoFisher) for 48 hours, at which point the medium samples were collected, filtered, 
and designated as 48-hour basal conditioned medium (48hr BCM) for use in DRG co-culture 
experiments (see below). As a control, media conditioned by uninduced MiMPCs and MSCs 
were designated as (48hr BCM). 
2.2.5 Detection of BDNF production from MiMPCs and MSCs 
Pre-treatment medium was aspirated and discarded. Conditioned medium (CM) was collected 
during each medium exchange during the NIM treatment period—The CM from the first NIM 
medium exchange was labeled as “Day 3” upon collection, and the final NIM medium exchange 
was labeled as “Day 7” upon collection. 48hr BCM was also collected from cells. These 
conditioned media were assayed for BDNF production using ELISA kits against BDNF (R&D 
Systems). Each ELISA was performed according to manufacturer’s instructions, using Costar 
96-well EIA/RIA, high binding, flat bottom plates (Corning Incorporated). 
2.2.6 Cell marker characterization with immunocytochemistry 
The culture medium was aspirated from the MiMPC, MSC, and Schwann cell control 
cultures (cell line sFN92.6, obtained from ATCC, Manassas, VA), and cells were washed with 
phosphate buffered saline (PBS; ThermoFisher). Cells were fixed with 4% paraformaldehyde 
(Electron Microscopy Sciences, Hatfield, PA) for 20 minutes, washed, and treated for 1 hour 
with hot 10 mM sodium citrate (Sigma-Aldrich) in 10% ethanol for antigen retrieval. After 
blocking with 5% FBS for at least 1 hour at room temperature, the cultures were incubated with 
primary antibodies for at least 4 hours at room temperature, or overnight at 4°C. 
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Immunofluorescence was carried out to localize the following cell markers on MiMPC, MSC, 
and Schwann cell cultures both before and after neurotrophic induction treatment: Schwann 
markers – GFAP (chicken IgY; cat. ab4674), P75/NGFR (rabbit IgG; cat. ab8874), S100B 
(rabbit monoclonal IgG; cat. ab52642); pluripotency markers - Sox2 (rabbit IgG; cat. ab97959), 
SSEA4 (mouse IgG; cat. 560307), and Oct3/4 (mouse IgG; cat. 560308); and MSC markers - 
CD44 (mouse monoclonal IgG; cat. MAB7045), CD73 (mouse monoclonal IgG; cat. ab81720) 
and CD105 (goat IgG; cat. AF1097). Primary antibodies were diluted in block buffer per 
manufacturer’s instructions. Samples were incubated with secondary antibodies, diluted in block 
buffer per manufacturer’s instructions, for 1 hour at room temperature. All cells were nuclear-
counterstained with 4’,6-diamidino-2’-phenylindole dihydrochloride (DAPI; ThermoFisher) for 
approximately 1 minute. SSEA4 and Oct3/4 antibodies were obtained from BD Biosciences, 
Franklin Lakes, NJ. CD44 and CD105 antibodies were obtained from R&D Systems. All other 
antibodies were purchased from Abcam (Cambridge, MA). Secondary antibodies used were 
AlexaFluor 488 conjugates from ThermoFisher (rabbit anti-goat IgG [cat. A27012], goat anti-
mouse IgG [A10680], goat anti-chicken IgY [A11039], donkey anti-rabbit IgG [A21206]). 
2.2.7 Gene expression analysis with real time RT-PCR 
RNA was isolated from induced MiMPCs using RNeasy Plus Mini Kit (Qiagen, 
Valencia, CA) according to manufacturer’s protocol. cDNA was synthesized using Invitrogen’s 
SuperScript III First-Strand kit (ThermoFisher). Real time RT-PCR was performed using SYBR 
Green PCR Master Mix from Life Technologies (ThermoFisher) and a StepOnePlus Real Time 
PCR machine (ThermoFisher). All gene expression levels were normalized to that of 18S rRNA 
as the control housekeeping gene. Primers for BDNF, GDNF, CNTF, and 18S rRNA were 
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obtained from Qiagen, and the primer for NGF was obtained from Integrated DNA Technologies 
(Coralville, IA).  
RT2 Profiler PCR Arrays (Qiagen) were used to assay for expression of human 
neurotrophins and receptors, and inflammatory cytokines and receptors. Arrays were run using 
RT2 SYBR Green ROX qPCR Mastermix (Qiagen) as per manufacturer’s protocols. PCR data 
analysis and heat map generation was done via Qiagen’s online RT2 Profiler PCR Array Data 
Analysis (version 3.5; http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php).  
2.2.8 Statistical analysis 
At least three independent experiments were conducted with three replicate samples per set of 
conditions were performed for each assay. All quantitative data are presented as a mean ± 
standard deviation. Significance of results was determined via Student’s T-test, or Tukey’s post-
hoc analysis as appropriate. All statistical analysis was performed in Microsoft Excel.  
2.3 RESULTS 
2.3.1 BDNF production by MiMPCs differentiated from iPSCs 
To determine the most advantageous parental-lineage of iPSCs and differentiation method 
toward a mesenchymal-like cell type that would yield the highest production of BDNF, MiMPCs 
and AEiMPCs were differentiated using either the mesenchymal growth medium (MGM) or 
embryoid body formation (EB) methods, as outlined above. Upon completing NIM treatment, 
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Day 7 conditioned medium (CM) was collected from each group, and BDNF production was 
confirmed with sandwich ELISAs as previously described.  
Day 7 CM showed that BDNF production, measured in pg/ml BDNF produced per 106 
cells, was highest in neurotrophically induced MiMPCs (NI-MiMPCs) generated via the MGM 
method (Figure 3A). BDNF levels from NI-MiMPCs were significantly higher than those seen in 
any group of AEiMPCs generated using either the MGM or EB methods. 
 From these results seen in Figure 3A, we concluded that MiMPCs were significantly 
superior to AEiMPCs in terms of neurotrophic support, so all the following characterizations and 
studies in this and subsequent chapters utilize MiMPCs differentiated from iPSCs of 
mesenchymal parentage. 
2.3.2 Progression of BDNF production by MiMPCs over time 
Figure 3B shows ELISAs against BDNF that are focused more closely on the secretory pattern of 
MiMPCs. Cells were neurotrophically induced, and conditioned medium from Days 3 and 7, and 
48-hour basal conditioned medium (48hr BCM) were assayed for BDNF production. BDNF 
production by MiMPCs was enhanced with NIM treatment. Conditioned medium assayed by 
ELISA during and after the induction period showed a consistent increase in BDNF 
concentrations compared to growth controls. The most marked increase in BDNF production by 
MiMPCs occurred at day 7 (p<0.05), with an approximately 5-fold increase in BDNF levels 
compared to GM-MiMPCs. Although this enhanced production of BDNF tapered off after the 
inductive medium was removed, conditioned medium collected 48-hours after induction still 
showed a 2-fold increase in BDNF concentration. While MSCs also showed a significant 
increase in BDNF production at Day 7 (p<0.05), the concentration was well below the levels 
 51 
detected in the MiMPC conditioned medium. The significant increase in BDNF production did 
not persist in conditioned medium taken from either MiMPCs or MSCs 48-hours after induction 
(48hr BCM). 
2.3.3 Morphological comparison of MiMPCs to MSCs 
Phase contrast microscopy showed that iPSCs grew in feeder-free colonies of small, 
undifferentiated cells (Figure 4A), and were able to differentiate into MiMPCs that exhibited an 
MSC/fibroblastic morphology (Figure 4B) comparable to control MSCs (Figure 4C). All 
microscopy fields shown in Figure 4 are representative of the cultures. 
2.3.4 MiMPCs express the same cell surface markers as MSCs and Schwann cells  
As previously stated, MiMPCs (induced mesenchymal progenitor cells derived from 
mesenchymal-lineage iPSCs using the MGM differentiation method) were chosen for all 
subsequent experiments. Through their usage and numerous passages, iPSCs retained expression 
of pluripotent markers SSEA4, Oct3/4 and Sox2 (Figures 5A). We further characterized the 
MiMPCs for neuronal lineage, as earlier work had only characterized these cells in terms of 
MSC tri-lineage differentiation and MSC-likeness (Figures 5B and 6). 
First, we showed the transition of surface markers from pluripotency to MSC and 
Schwann markers. Feeder-free iPSCs were grown to confluency and differentiated into MiMPCs. 
On the third day of the differentiation period, a group of MiMPCs were set aside, 
paraformaldehyde-fixed and stained for mesenchymal (CD44, CD105 and CD73), Schwann 
(GFAP, S100B and p75/NGFR), and pluripotent markers (SSEA4, Oct3/4 and Sox2). On day 3, 
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it was shown that MiMPCs expressed mesenchymal markers CD44 and CD105, but was only 
weakly positive for CD73. MiMPCs were positive for all Schwann cell markers, and were 
positive for Sox2, faintly positive for Oct3/4, and negative for SSEA4 (Figure 5B). This gave us 
reason to extend the differentiation period in the protocol out to 7 days total, in order to give the 
cells more time to fully differentiate into a mesenchymal-like cell. With a 7-day differentiation 
protocol, cells were strongly positive for all mesenchymal markers, and negative for all 
pluripotent markers (Figure 6).  
These cells have been shown to be a distinct population of cells that express 
mesenchymal cell markers, such as CD44, CD73 and CD105, and are capable of behaving 
similarly to MSCs in that they can be differentiated along osteogenic, as well as adipogenic and 
chondrogenic lineages [98]. Immunohistochemistry also showed that MiMPCs, like MSCs and 
Schwann cell controls, expressed mesenchymal markers (CD44, CD105 and CD73) and 
neurologically relevant cell markers (GFAP, S100B and p75-NGFR), the expression of which 
was not affected upon neuroinductive treatment (NI-MiMPCs and NI-MSCs). Similarly, non-
induced MiMPCs and MSCs grown in growth medium (GM-MiMPCs and GM-MSCs) were also 
positive for mesenchymal and Schwann cell markers (Figure 6). 
2.3.5 Changes in gene expression after neurotrophic induction 
Analysis of gene expression using PCR array panels for neurotrophins and inflammatory 
cytokines showed an upregulation in genes relevant to nerve regeneration, including IL-6, LIF, 
IL-1B, and osteopontin (SPP1) in NI-MiMPCs, compared to GM-MiMPCs and to MSC groups 
(Figure 7). ELISA results confirmed that the upregulated genes correlated with increased, 
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corresponding protein levels in cell culture supernatant. We did not conduct an ELISA to detect 
IL-1β, as 10 ng/ml of IL-1β was included in the neuroinductive medium.  
As there is only approximately a 40% correlation between mRNA upregulation and 
protein production [145-147], we used ELISAs to confirm the production of each of the 
aforementioned factors.  
2.3.6 Production of non-neurotrophins by MiMPCs after neurotrophic induction 
Our previous ELISA data show that under normal growth medium conditions, control 
MSCs produced low levels of BDNF. Following neurotrophic induction, NI-MSCs produced 
significantly higher levels of BDNF. Although MiMPCs exhibited many of the same 
characteristics seen in MSCs, our results showed that GM-MiMPCs were able to produce small 
amounts of BDNF; in fact, BDNF production levels from GM-MiMPCs were comparable to 
those seen from induced MSCs. However, our ELISAs detected significantly higher BDNF 
production from MiMPCs after treatment with NI medium (Figure 3).  
Other cytokines have previously been shown to improve nerve regeneration after injury, 
among them IL-6 [54, 55], LIF [51, 148], osteopontin, clusterin [149], and osteonectin [32, 33, 
58]. Interestingly, the cytokine ELISA results on medium samples conditioned by NI-MiMPCs 
and NI-MSCs also demonstrated marked increases in the concentration of these factors (Figure 
8). 
We assayed conditioned medium collected at days 3 and 7 of the NI medium treatment, 
as well as basal medium conditioned for 48-hours after the NIM treatment period was over. The 
ELISA data in Figure 8 show that IL-6 and osteonectin production remained relatively constant 
throughout and after the induction period (Figure 8A, C and E), but there was a significant 
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decrease in osteopontin and LIF production during and after the NIM treatment period (Figure 
8B and D). Since osteopontin and LIF concentration levels were low in the NI-MiMPC 
conditioned basal medium, we focused on BDNF, IL-6 and osteonectin for the set of experiments 
investigating the effects of MiMPCs and MSCs of neurite extension in DRG cultures in the 
following chapter. 
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Figure 3. Production of BDNF by NI- MiMPCs, AEiMPCs, and MSCs quantified by 
ELISAs 
(A) Comparison of conditioned medium taken from Day 7 of induction cultures from MiMPCs 
and AEiMPCs, differentiated via the mesenchymal growth medium method (MGM), or 
embryoid body formation method (EB). Neurotrophically induced MiMPCs (NI-MiMPCs) 
differentiated from iPSCs via the mesenchymal growth medium (MGM) treatment method 
showed significantly enhanced (p<0.05) BDNF production compared to all other groups. (B) 
Conditioned neuroinductive media taken from days 3 and 7 of induction culture, and conditioned 
basal medium taken from cultures 48 hours post-induction (48hr BCM), were assayed for levels 
of BDNF. Groups marked with a * indicate a significant difference (P<0.05) compared to growth 
medium control (GM) groups. All ELISAs are expressed in pg/mls produced per million cells. 
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Figure 4. Morphology of MiMPCs and MSCs examined by phase contrast microscopy   
(A) Undifferentiated colonies of human iPSCs reprogrammed from human bone marrow MSCs 
[98]. Cells grew to confluent colonies on Matrigel, in feeder-free culture. (B) Confluent MiMPC 
cultures differentiated from iPSCs. All MiMPC cultures resembled MSCs in morphology, with 
no remaining iPSC morphology. (C) Confluent control MSCs isolated from human bone marrow 
(passage 5).  Images taken at 4x. Bar = 560 µm. 
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Figure 5: Expression of various stem cell markers during conversion of iPSCs to MiMPCs 
detected by immunofluorescence 
MiMPCs were fixed and immunofluorescently stained on the third day of differentiation; 
colonies of confluent iPSCs served as controls. Cells were stained for MSC markers (CD44, 
CD73, and CD105), Schwann cell markers (GFAP, p75/NGFR, and S100B), and pluripotent 
stem cells markers (Sox2, SSEA4, and Oct3/4). All cells were counterstained with DAPI. (A) 
iPSCs were negative for MSC and Schwann cell markers, but stained positively for pluripotent 
markers, indicating the maintenance of stemness throughout culture and passaging. (B) MiMPCs 
cells were strongly positive for CD44 and CD105, and weakly positive for CD73. MiMPCs also 
stained positive for all Schwann cell markers, positive for Sox2, weakly positive for Oct3/4, and 
negative for SSEA4, showing their transition and demonstrating the need for long differentiation 
period. All cells were imaged at 10x magnification. Bar = 220 µm. 
 58 
 
 
Figure 6: Expression of neurological and mesenchymal cell markers in MiMPCs and MSCs 
during neurotrophic induction examined by immunofluorescence 
MiMPCs and MSCs were cultured in neurotrophic induction medium (NIM) or growth medium 
(GM). Neurotrophically induced MiMPCs and MSCs were fixed and stained with antibodies 
against MSC markers (CD44, CD73, CD105) and Schwann cell markers (GFAP, p75/NGFR, 
and S100B). Neurotrophically induced and non-induced MiMPC and MSC cultures stained 
positive for all MSC and Schwann cell markers. Schwann cells were stained as a control, and 
were positive for all markers. All cells were counterstained with DAPI. All images were taken at 
10x magnification and are representative of all fields. Bar = 220 µm.   
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Figure 7: Heat maps of PCR gene expression assay analysis of NI-MiMPCs 
MiMPCs and MSCs were cultured in neurotrophic induction medium (NIM) or growth medium 
(GM).  PCR arrays targeting (A) human neurotrophins and receptor genes; and (B) human 
inflammatory cytokines and receptor genes were performed and heat maps were generated using 
Qiagen’s online RT2 Profiler PCR Array Data Analysis tool (version 3.5). For both heat maps, 
mRNA levels in NI-MiMPCs were normalized against GM-MiMPCs and GM-MSCs control 
groups. Among the neurotrophins and receptor genes (A), upregulation was detected in mRNA 
levels of IL-1B, IL-6 and LIF, with fold changes of 65.86, 6.76, and 4.01, respectively. Among 
the inflammatory cytokines and receptor genes (B), upregulation in mRNA levels was detected 
for genes relevant to nerve regeneration, including a 11.86 fold increase in SPP1. 
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Figure 8: Production of factors by NI- MiMPCs and MSCs, quantified via ELISA 
MiMPCs and MSCs were cultured in neurotrophic induction medium or growth medium. 
Conditioned media taken from days 3 and 7 of induction culture, and basal conditioned medium 
taken from cultures 48 hours post-induction (48hr BCM). The conditioned media assayed 
include those from MiMPCs (induced, NI-MiMPCs; uninduced, GM-MiMPCs), and from MSCs 
(induced, MI-MSCs; uninduced, GM-MSCs), as well as basal medium (controls). Medium was 
assayed for levels of (A) Osteonectin, (B) Osteopontin, (C) IL-6, (D) LIF, and (E) clusterin. All 
ELISA results are expressed in pg/ml or ng/ml produced per million cells. Medium taken from 
NI-MiMPC cultures contained high levels of all assayed factors compared to GM-MiMPCs, NI-
MSCs, and GM-MSCs. Osteonectin, IL-6, and clusterin exhibited relatively constant secretion 
levels, while osteopontin and LIF showed decreased expression levels during induction treatment 
and the 48-hour post-induction period. *, p <0.05, denotes significance of NI groups of each cell 
type compared to their respective GM controls.  
 62 
2.4 DISCUSSION AND CONCLUSIONS 
No defined protocol exists for the majority of iPSC differentiations. Multiple literature sources 
describe their own novel protocol for differentiation along various lineages including 
mesenchymal stem cells, cardiomyocytes, and hepatic cells [83, 98, 150-153]. In our past 
studies, it was assumed that published protocols for human embryonic stem cell (hESC) 
differentiation will have the same effect on iPSCs. While this can add flexibility to a study and 
provide leeway in terms of optimization, it should be noted that different methods could cause a 
difference in cell function or differentiation capability, even if the desired phenotype is expressed 
(i.e., morphology, expression of cell markers) [92]. For this reason, this study begins with 
characterization and comparison of MiMPCs and AEiMPCs in the context of neurotrophic 
potential, even though both cells have been previously characterized in earlier work by 
Diederichs in the context of adipogenic, chondrogenic, and osteogenic differentiation capabilities 
[92].  
 While EB formation has previously been reported as a viable way to generate MSC-like 
cells from either hESCs or iPSCs, our studies show that EB formation, as far as BDNF 
production, is not a favorable method to generate MiMPCs. The MGM method, however, has 
proven to be amenable to BDNF production. It is possible that since embryoid body formation 
inherently implies that not all cells (i.e. cells in the inner portion of EBs) will be exposed to the 
same chemical microenvironment, the MiMPCs generated from the EB method are thus more 
heterogeneous, and perhaps differ more drastically in their ability to produce BDNF. It may be 
an interesting future study to detail the differences between these two methodologies and how it 
may influence the secretome of the MiMPC, particularly as related to neurotrophic support. 
Because neurotrophin production capacity is of utmost importance for nerve regeneration, this 
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parameter has been chosen to determine which cell type (MiMPCs or AEiMPCs) and which 
differentiation method (MGM or EB) was most suitable for this purpose. 
 Our results indicated that NI-MiMPCs were capable of producing far more BDNF than 
NI-AEiMPCs, when neuroinductive treatment protocol was used (Figure 3). However, it did not 
seem that the neuroinductive protocol was capable of promoting production of CNTF, NGF, NT-
3 or GDNF. Initial trials of ELISAs appeared to detect trace levels of CNTF and NGF from both 
NI- MiMPCs and MSCs, but the results could not be reliably reproduced. Multiple literature 
sources have stated that MSCs can produce detectable levels of neurotrophins including CNTF, 
NGF and GDNF [5, 71, 154]. It is possible that our control MSCs are not producing all the 
expected neurotrophins due to factors beyond our control, such as the age of the patient from 
whom the cell was isolated (60-year-old male), environmental exposures, and any pre-existing 
condition that may have demanded an orthopedic surgery from the patient in the first place. 
Although the MSCs from which our iPSCs were reprogrammed were isolated from a middle-
aged patient, and the iPSC karyotype showed no abnormality after 13 passages [98], there is a 
possibility that this resistance to producing certain neurotrophic factors is due to epigenetic 
factors that we have not accounted for. 
 The MiMPCs are capable of producing physiologically relevant levels of BDNF. Under 
normal conditions, NGF is typically expressed in the peripheral nerve, and BDNF synthesis is 
highest in the central nervous system, however, post-injury, BDNF mRNA and BDNF activity 
increase in peripheral nerves and Schwann cells, reaching up to 10 times the levels seen from 
NGF [155]. Therefore, it may be more physiologically relevant for MiMPCs to secrete high 
levels of BDNF compared to other neurotrophins. 
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 It is noteworthy that parametric cyclic-AMP assays on conditioned medium did not yield 
results from any cell type (data not included). Adenosine cyclic monophosphate (cAMP) is a 
ubiquitous secondary messenger molecule in eukaryotic cells. Multiple studies have shown that 
elevated levels of cAMP can increase both myelin production by Schwann cells as well as axonal 
regeneration in nerves [156]. Although data on the effect of extracellular cAMP on nerve 
regeneration are limited, what little information there is seems to indicate that cAMP can have 
neurotrophic effects and enhance nerve regrowth [157]. However, neither induced nor non-
induced MiMPCs or MSCs produced detectable cAMP into conditioned medium from either day 
3, day 7 or 48-hours post-NIM treatment. It is likely that due to the presence of forskolin and 
IBMX in the NI-medium, cAMP levels were indeed elevated in day 3 and day 7 conditioned 
medium at the very least, but could have remained undetectable due to either the retention of 
cAMP within the cell, or degradation of the molecule despite immediate freezing upon sample 
collection. Furthermore, the published literature has reported that BDNF itself can increase 
cAMP levels by activating the ERK pathway, which leads to inhibition of phosphodiesterase4, 
which hydrolizes cAMP [158]. As BDNF production was high in NI-MiMPCs and NI-MSCs, 
there is further reason to believe that intracellular cAMP levels were elevated. Both renal[159] 
and muscle[160] cells have mechanisms to regulate the efflux of cAMP-adenosine to their 
respective extracellular matrices, though clearly it is a specialized process that the MiMPCs and 
MSCs do not possess.  
A simple, morphological comparison showed that the MiMPCs differentiated from iPSCs 
resembled typical MSC cultures, while the original iPSC colonies did not resemble MSCs or 
MiMPCs. iPSC colonies were negative for all mesenchymal and Schwann cell markers, but were 
positive for pluripotent markers SSEA4, Sox2, and Oct3/4. Previous data from our lab confirmed 
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that the iPSCs used here were true pluripotent cells [98]. From this, we can ascertain that our 
iPSCs retained desirable qualities and remained pluripotent throughout their usage. 
Characterization of MiMPCs showed positive staining for many of the same cell surface markers 
as both MSCs and Schwann cells, including CD44, CD73, CD105, GFAP, S100B, and 
P75/NGFR.   
The expression of p75/NGFR should be noted. A study by Bentley et al. (2000) showed 
that the lack of p75/NGFR was linked to a deficit in Schwann cell migration and coverage, as 
well as a substantial reduction in nerve bundle and axon formation. However, there have also 
been reports stating the negative effects of p75/NGFR after injury, and that it may have a role in 
axon apoptosis and death signaling pathways [161, 162]. While the majority of this study utilizes 
conditioned medium taken from these cells to use in DRG culture, we can include these cells in 
future in vivo studies along with a p75/NGFR inhibitor to prevent any potentially negative effects 
of p75/NGFR signaling. It does not appear that the literature related to p75/NGFR can confirm 
whether or not the presence of p75/NGFR is helpful or harmful in terms of axon regeneration 
after injury, although some data suggest that a p75/NGFR antagonist can have neuro-protective 
effects on retinal ganglion [163]. Therefore, it may be beneficial in future studies to knock down 
the expression of p75/NGFR in MiMPCs when co-culturing the cells with DRGs in electrospun 
scaffolds. 
MiMPCs and MSCs are also capable of producing factors shown in previous works by 
other groups to enhance nerve regeneration, such as osteonectin, osteopontin, IL-6, LIF and 
clusterin (Figure 8).  Osteonectin is a secreted matricellular protein that plays a role in bone 
mineralization by binding calcium to collagen [164]. Previous studies have shown that 
osteonectin can also play a role in promoting neural cell survival and initiating extension 
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outgrowth [33, 58]. It has also been suggested that osteonectin and BDNF may work 
synergistically to promote neurite outgrowth [32].  
Multiple studies have already shown the benefits of having angiogenic factors present 
during nerve regeneration [69, 71, 210], and that angiogenesis and restoration of blood supply 
improves functional recovery. Man, et al showed that the presence of VEGF-overexpressing 
MSCs transplanted in vivo increased neurite extensions and Schwann cell proliferation [69]. At 
sites of injury, Mohammadi showed that local administration of exogenous VEGF would 
improve functional recovery in rats [211].However, VEGF is unlikely to be playing a role in our 
studies, as VEGF production is a point of difference between the secretomes of MiMPCs and 
MSCs. While MSCs are fully capable of secreting VEGF regardless of neuroinductive treatment, 
MiMPCs can secrete VEGF only when incubated in neuroinductive medium—no VEGF 
production was apparent in the GM or any basal conditioned medium (BCM) groups (Figure 19). 
In addition, DRGs were cultured only in BCM collected from cells. Furthermore, osteonectin is 
present in high quantities in the conditioned medium, and work by Kupprion et al suggests that 
osteonectin is able to bind VEGF and prevent its interaction with its receptor [165]. It is 
therefore likely that even if trace VEGF levels were present in MiMPC basal conditioned 
medium and escaped detection in the ELISAs, the effects of such minute levels would be 
inhibited by the comparatively high levels of secreted osteonectin. As MiMPCs will not be in NI 
medium when transplanted in vivo, it is likely that MiMPCs may not be able to support 
angiogenesis, and thus supplying exogenous VEGF or MiMPC transfection with VEGF-
expressing plasmids may be required.  
Osteopontin is a cell adhesion molecule that is expressed on a wide variety of cell types, 
and has been implicated in cell survival and inflammatory regulation [166]. There have been a 
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limited number of studies to suggest that osteopontin also plays a role in nerve regeneration, 
although there seems to be more of an association between osteopontin and motor neuron 
outgrowth rather than sensory neuron outgrowth [149, 167].  
Clusterin is another commonly expressed glycoprotein found in most tissues [168]. As it 
is a commonly found molecule, many studies have found various roles for clusterin. It has been 
implicated in the pathogenesis of Alzheimer’s [169], while another study found that clusterin 
alleviated peripheral neuropathy in rats [170]. Other studies have found that mRNA levels of 
clusterin were increased after peripheral nerve injury, and as clusterin is involved in lipid 
recycling, it suggests that the presence of this molecule at the site of injury aids Wallerian 
degeneration and Schwann cell proliferation [171, 172]. Meanwhile, clusterin may signal 
through the megalin receptor, a pathway which has been shown in the DRG to selectively 
promote sensory neuron outgrowth [173, 174].  
It is well established that cytokines of the IL-6 superfamily, which includes IL-6 and LIF, 
are able to activate the Jak/STAT3 pathway, an important signaling pathway in neurite axon 
extension [175, 176]. Our ELISAs showed that higher concentrations of only certain growth 
factors and cytokines were maintained both during and after the neuroinductive treatment period 
had concluded, including IL-6, but not LIF. While it is likely that the increased concentration of 
IL-6 means that this cytokine will play more of a role than LIF, studies have shown that LIF is 
more potent than IL-6, and may be able to exert the same effects at a lower concentration [177]. 
However, the potency of LIF versus IL-6 was assessed on microvascular and endothelial cells, so 
it may still be premature to assume that LIF is having the same effect in nerve regeneration. 
Taken together, it is probable that these properties of the MiMPC may have a positive 
influence on nerve regeneration, possibly superior to those seen from MSCs. If the conditioned 
 68 
medium from NI-MiMPCs can be collected, or if the cells themselves can be harvested, it is 
conceivable that this medium or the cells can be used in procedures that enhance nerve 
regeneration. 
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3.0  NEUROTROPHICALLY INDUCED MIMPCS ENHANCE COMPLEXITY OF 
DORSAL ROOT GANGLION NEURITE EXTENSIONS INDEPENDENTLY OF 
NEUROTROPHIN SIGNALING 
3.1 INTRODUCTION 
It is well established in the literature that classic neurotrophins, such as BDNF, NT-3, 
NT-4/5 and NGF, play major roles in neuronal survival, maintenance, and repair. In the 
peripheral nervous system, Schwann cells are the main providers of such neurotrophins in 
addition to forming the myelin sheath.  
Neurotrophins and extracellular matrix (ECM) proteins also play a part in neuritogenesis, 
a complex process where neurite extension processes grow out from the main body of the nerve 
cell. Neurites form from localized lamella collapse around microtubules, and their distal growth 
cones form from uncollapsed lamella. These growth cones and microtubules extend the neurite 
away from the cell body. These nascent neurite processes later mature into axons and dendrites 
[178].  
The aforementioned neurotrophic ligands signal through the tropomyosin receptor 
kinases (Trk receptors), located in the plasma membrane of nerve cells. Three types of Trk 
receptors are found in human nerve cells—TrkA, TrkB, and TrkC. Typically, NGF is specific for 
TrkA, NT-4/5 and BDNF signal through TrkB, and NT-3 signals through TrkC. However, the 
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specificity of the ligands for their respective Trk receptor can depend upon the Trk isotype 
present. Various signaling pathways through Trk receptors are responsible for a multitude of 
functions, including differentiation, regulation of synaptic strength, plasticity, ion channel 
activity, neurotransmitter receptors, and modulates exo- and endocytosis of synaptic vesicles 
[179].  
While the Trk receptor mediate a variety of nerve-related functions, they have been 
implicated in both neurogenic and non-neurogenic tumor growth, especially when they form 
oncogenic gene fusions. These chimeric Trk proteins are typically constitutively active, or have 
hyperactive kinase function, resulting in oncogenic potential. Although these oncogenic fusions 
were originally discovered in 1982, renewed interest in these chimeric proteins did not occur 
until recently, as personalized medicine and targeted therapies related to Trk receptors were not 
possible until the recent discovery of NTRK1, NTRK2, and NTRK3 gene fusions. For this 
reason, pharmacological blockers against the Trk receptor have been synthesized, some of which 
are in or approaching clinical trials.  
One such drug is GNF5837, a potent pan-Trk receptor antagonist. It is an oxindole urea 
inhibitor with high binding affinity to TrkA, TrkB, and TrkC that targets the ATP binding cleft 
and an adjacent hydrophobic pocket. It has highly anti-proliferative effects and has been found to 
reduce tumors in mammals [180].  
Cyclotraxin-B is a selective, potent cyclical peptide that allosterically modulates the 
action of TrkB receptors by altering the conformation of TrkB. Both BDNF-dependent and -
independent activities were inhibited. It has been shown to have anxiolytic effects in mice 
without anti-depressant activity, thereby demonstrating its ability to cross the blood-brain barrier. 
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Due to these properties, cyclotraxin-B may be useful as a tool both for examining the effects of 
BDNF and as a potential treatment for brain disorders [181]. 
BDNF, IL-6 and LIF, previously established to be produced by MiMPCs, are also 
capable of activating the Janus kinase/signal transducer and activator of transcriptions 
(Jak/STAT) pathway to promote nerve regeneration after axotomy [37, 182]. In the peripheral 
nerve, phosphorylated STAT3 is increased following lesions. Cytokines in the IL-6 superfamily 
(i.e., IL-6 and LIF) facilitate this response by activating the receptor/gp130 complex which 
signals downstream through STAT3 [176]. STAT3 is associated with neuron regeneration, as it 
co-localizes with survival markers in nerves post-injury, and knockout models have exhibited 
deficiencies in neuronal function and survival after axotomy [182]. Lin et al showed that BDNF 
promoted neurite growth through the Jak/STAT pathway in mice pelvic ganglion by 
administering an inhibitor AG490 and confirming that BDNF-enhanced neurite growth was 
truncated [38].  
The previous chapter showed enhanced BDNF production from NI-MiMPCs compared to 
GM-MiMPCs or MSCs. We hypothesize that based on the neurological studies found in the 
literature and the characterization of our MiMPCs, the conditioned medium from NI-MiMPCs 
will be able to enhance neuritogenesis from dorsal root ganglion (DRG) cultures. This effect was 
assessed in embryonic DRGs cultured on tissue culture plastic. In order to tease apart the 
MiMPC secretome and determine if secreted BDNF was truly the effector molecule, conditioned 
medium was supplemented with Trk receptor inhibitor drugs.  
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3.2 METHODS 
3.2.1 Tissue culture plate preparation 
100ng/ml poly-D-lysine solution was prepared and dispensed into each well of a 12-well plate. 
Polylysine was allowed to coat the plate for 3 days at 4˚C on a rocking platform, after which it 
was aspirated from wells, and wells were washed with sterile 1xPBS. 10 µg/ml laminin was 
prepared and used as a supplemental coating, and was allowed to coat the plate for 3 days at 4˚C 
on a rocking platform. Both poly-D-lysine and laminin were purchased from Sigma-Aldrich (St. 
Louis, MO). 
3.2.2 Isolation of dorsal root ganglia (DRGs) 
DRGs were harvested from day 9 chick embryos, using a previously described protocol [183]. 
The isolated DRGs were plated one per well on a 12-well plate coated with poly-d-lysine and 
laminin as previously described.  
The DRGs were allowed to adhere to the substrate in medium consisting of DMEM-F12 
and 5% FBS, further supplemented with 10 ng/ml each of basic fibroblast growth factor (FGF-2), 
epithelial growth factor (EGF) and nerve growth factor (NGF). After a 3-day settlement period, 
medium on DRGs were exchanged for 48-hour basal conditioned medium (48hr BCM) collected 
from either (1) NI-MiMPCs, (2) GM-MiMPCs, (3) NI-MSCs, or (4) GM-MSCs. Control DRGs 
were cultured in unconditioned basal medium consisting of DMEM-F12, 5% FBS, ITS-X, and 
pen-strep. All DRGs were cultured for 5 days. Cultures were then immunostained as outlined 
previously. Briefly, DRGs were fixed with 4% paraformaldehyde, incubated in hot sodium 
 73 
citrate for antigen retrieval, blocked in 5% FBS and incubated with anti-heavy neurofilament 
primary antibody (Abcam, Cambridge, MA) diluted to 1:10,000 overnight at 4°C. Secondary 
antibody AlexaFluor 488 conjugate (ThermoFisher, Waltham, MA) was allowed to incubate for 
1 hour at room temperature at a 1:300 dilution with blocking buffer. Neurite outgrowth 
quantitatively assessed via Sholl analysis (see below). 
3.2.3 Optimizing Trk receptor inhibitor drug studies 
DGRs were isolated as previously described, and plated on polylysine/laminin coated 12-well 
tissue culture plates. DRG growth control medium was supplemented with 10 ng/ml each of 
NGF, EGF and FGF. For the BDNF growth control, 20 ng/ml of BDNF was added to DRG 
control medium in addition to the aforementioned growth supplements. Negative growth control 
cultures consisted only of basal medium (DMEM-F12, 5% FBS, ITS and PSF). DRG cultures 
were separated into groups that were additionally supplemented with 100 nM, 500 nM, and 1 µM 
of cyclotraxin-B (ThermoFisher), a selective Trk-B inhibitor; and 12 nM and 24 nM of 
GNF5837, a selective and potent pan-Trk receptor inhibitor (Sigma-Aldrich). Sholl analysis 
[184] was used to determine optimal drug and concentration use for decreasing number of 
neurite extensions.  
3.2.4 Trk receptor inhibition 
To assess the involvement of Trk receptor-mediated neurotrophin signaling, the Pan-Trk 
inhibitor, GNF-5837 (Sigma-Aldrich), was used at a concentration of 24 nM, which exceeded 
IC50 values (7 – 11 nM for TrkA, TrkB, and TrkC) reported in the literature [180]. GNF-5837 
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was supplemented to 48 h BCM from NI-MiMPCs and control MiMPCs, and NI-MSCs and 
control MSCs, which were subsequently used to culture chick DRGs for 4 days. Cultures were 
paraformaldehyde-fixed and immunostained for heavy neurofilament, and branching complexity 
of neurite outgrowth was assessed. 
3.2.5 Jak/STAT inhibition 
To assess the involvement of JAK/STAT3-mediated signaling, cucurbitacin I, an 
inhibitor of the JAK2/STAT3 signaling pathway that suppresses the levels of tyrosine 
phosphorylated STAT3 [185], was used at a concentration of 60 nM. Cucurbatacin-I was 
supplemented to 48h BCM from NI-MiMPCs and control MiMPCs, and NI-MSCs and control 
MSCs, which were subsequently used to culture chick DRGs for 4 days. Cultures were 
paraformaldehyde-fixed and immunostained for heavy neurofilament, and branching complexity 
of neurite outgrowth was assessed (see below).  
3.2.6 Immunofluorescent staining of DRG cultures 
DRG/MiMPC co-cultures were fixed in buffered 4% paraformaldehyde and permeabilized with 
10 mM sodium citrate in 10% ethanol heated to just under boiling temperature in the microwave 
for 1 hour. After blocking in 5% FBS, cultures were incubated with mouse anti-heavy 
neurofilament (1:500; Abcam, Cambridge, MA) in block buffer overnight at 4°C. After rinsing, 
cultures were then incubated with fluorescently labeled secondary antibodies (1:300; AlexaFluor 
488 goat IgG, IgM; Invitrogen, Carlsbad, CA) for 1 hour at room temperature. Co-cultures that 
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included MiMPCs/MSCs were also nuclear-stainted with DAPI (1:10,000; Invitrogen, Carlsbad, 
CA) according to the supplier’s protocol. 
3.2.7 Quantitation of neurite branching complexity 
Fluorescent DRG image tiles were processed with MetaMorph (Molecular Devices, 
Sunnyvale, CA), and digitally stitched together using open source software Fiji/NIH ImageJ 
(developed at the NIH, Bethesda, MD) [186]. All greyscale images were thresholded to create 
binary bitmap images. Neurite extension densities were measured using the Sholl analysis plugin 
function within Fiji. The algorithm automatically retrieves data from 2D or 3D images to perform 
a regression analysis and generate the metrics for Sholl-based dendrite arborization [187]. Fiji 
Sholl plugin was set such that each radius step consisted of 50 pixels with each radius being 
sampled 3 times. Critical values (Cvs; the measurement of the Sholl analysis that corresponds to 
the point of maximum branching density, see Figure 20 for a representative example of a Sholl 
analysis graph) were taken from each Sholl measurement and averaged to generate bar graphs. It 
should be noted that the graph in Figure 20 is only representative, and that the maximum number 
of neurite extensions may occur at different radii depending on the sample. All images were 
taken at 4x magnification using an inverted microscope (Olympus IX81) with a motorized stage 
controlled through MetaMorph, and the scale used was 620 pixels = 1 mm.  
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3.2.8 Statistical analysis 
All data were presented as means ± standard deviation, unless otherwise stated. Statistical 
significance was determined by Student’s T-test, Levene’s test and Games Howell post-hoc tests 
as appropriate.  
3.3 RESULTS 
3.3.1 Morphological comparison of dorsal root ganglion (DRG) neurite extension 
complexity 
All DRGs were dissected from 9-day old chick embryos. We evaluated the effect of 
neurotrophically induced cells on nerve growth by culturing DRGs with conditioned medium 
from NI-MiMPCs and NI-MSCs (Figure 9).  
A morphological examination of immunofluorescence staining showed that DRGs 
cultured with both conditioned medium from NI and GM-MiMPCs appeared to have 
significantly improved neurite outgrowth, compared to either control cultures or those cultured 
with conditioned media from NI-MSCs (Figure 9A-E). DRGs cultured in conditioned medium 
from GM-MSCs also exhibited significantly enhanced neurite outgrowth. This demonstrated that 
MSCs and MiMPCs, particularly the latter, were producing factors that enhanced nerve growth. 
DRG neurite extension complexity was evaluated by Sholl analysis using ImageJ to 
quantitatively confirm these morphological findings. 
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3.3.2 Sholl analysis shows enhanced neurite branching complexity of DRGs grown in 
MiMPC conditioned medium  
Sholl analysis confirmed that conditioned medium from both NI-MiMPCs and GM-MiMPCs 
yielded significantly enhanced neurite branching complexity in DRG cultures compared to 
controls. Complexity increased 2.1 and 2.3 times that of controls when DRGs were cultured in 
conditioned medium from NI-MiMPCs and GM-MiMPCs respectively. Sholl analysis also 
confirmed that DRGs cultured in conditioned medium from GM-MSCs but not NI-MSCs 
exhibited significantly enhanced neuritogenesis. Conditioned medium collected from GM-MSCs 
similarly increased neurite complexity by about 2.3 times that of controls. However, DRGs 
cultured in NI-MSC conditioned medium showed only 1.7 times the branching complexity 
compared to controls, and thus was not statistically significantly different from controls (Figure 
9F-G). 
3.3.3 GNF5837 reduced neurite branching in Trk-receptor inhibition DRG cultures 
In our pilot studies to determine optimal drug and concentration use, we compared the Sholl 
results between DRGs treated with pan-Trk receptor inhibitor GNF5837 and TrkB-receptor 
inhibitor cyclotraxin B. With both drugs, we found an inverse relationship between the number 
of neurite extensions and the drug concentration used. The decrease in neurite extension 
complexity was most pronounced in DRG cultures containing 1uM cyclotraxin-B or 24nM 
GNF5837 (Figure 10). In these cultures, neurite extensions were significantly decreased from 
those seen in positive growth control cultures supplemented with 10ng/ml of each NGF, EGF, 
and FGF, and 20ng/ml of BDNF. 
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3.3.4 Conditioned medium from neurotrophically induced MiMPCs enhance DRG 
neurite complexity in the presence of GNF5837 
The involvement of BDNF was tested by examining the effect of inhibiting the action of 
the neurotrophin Trk-receptor on DRG neurite outgrowth.  The pan-Trk receptor inhibitor drug, 
GNF5837 (24 nM), was co-administered to the MiMPC conditioned medium treated DRGs. As 
shown in Figure 11A-E, DRG growth appeared to be only slightly reduced in complexity and 
size. The Sholl analysis results showed that, upon GNF5837 co-treatment, all conditioned 
medium treated groups, except for medium collected from NI-MiMPCs, experienced a marked 
decrease in neurite extension density (decreases of 45-60% measured branching density, as 
opposed to only a 10% decrease in measured branching density in cultures containing NI-
MiMPC conditioned medium) (Figure 11F-G). Furthermore, as our cells did not produce 
detectable levels of the neurotrophins, NGF, NT-3, CNTF or GDNF, with the latter two not 
acting through the Trk receptors, this observation suggested that additional non-neurotrophic 
factors were likely being produced by NI-MiMPCs that were capable of initiating neurite 
extensions, acting independently of the Trk-receptors.  
3.3.5 Presence of cucurbitacin-I in conditioned medium from neurotrophically induced 
MiMPCs does not abolish neurite outgrowth 
As multiple published investigations have suggested a role for IL-6-type cytokines in nerve 
regeneration [55, 56, 176], and as our results suggested that BDNF was unlikely to be the only 
factor involved in enhancing neurite extension density, we sought to block the effects of IL-6 to 
determine if neurite density would be affected. As IL-6 signals through the Jak/Stat pathway, we 
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targeted the inhibition of this pathway with a pharmacological blocker, cucurbitacin-I [185]. The 
most immediate observable effect from cucurbitacin-I administration was the truncation in 
neurite extension length. However, a morphological examination did not make it obvious 
whether neuritogenesis had also suffered (Figure 12A-E).  
 Results from the Sholl analysis showed that treatment with cucurbitacin-I decreased 
neurite complexity to the extent that the effects of the conditioned medium from non-induced 
cells was no longer significantly different from that seen in control cultures. However, 
conditioned medium from NI-MSCs still enhanced complexity of DRG neurite extensions 
compared to controls (Figure 12F-G). While statistical analysis determined that CM from NI-
MiMPCs no longer yielded a significant improvement, the average DRG culture still exhibited 
increased neuritogenesis compared to controls. The more pronounced effect of the addition of 
cucurbitacin-I to the DRG cultures, however, was the decrease in observed neurite extension 
length, which could not be accurately measured on tissue culture plastic due to the disorganized 
growth patterns typical of DRGs cultured on tissue culture plastic (TCP).  
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Figure 9: Morphological and quantitative comparison of DRG neurite extension branching 
complexity 
Dorsal root ganglia (DRGs) are cultured for 5 days in medium conditioned for 48 hours by (A) 
NI-MiMPCs, (B) NI-MSC, (C) GM-MiMPCs, or (D) GM-MSCs. Controls in (E) show DRGs 
cultured for 5 days in unconditioned basal medium. All DRGs were stained with anti-heavy 
neurofilament antibody, an intermediate filament found in neurons, and imaged. (F) Sholl 
analysis on DRGs show that conditioned medium (CM) collected from NI-MiMPCs significantly 
enhanced neuritogenesis over controls, but DRGs cultures in CM from NI-MSCs did not show 
improvement. Sholl measuring radii ranged from: 4.52-9.11mm (MiMP NIM), 2.03-6.135mm 
(MSC NIM), and 4.12-6.22mm (controls) (G) Sholl analysis measures the number of 
intersections, and therefore, the number of neurite extensions, on images, which show that GM- 
MiMPCs and MSCs significantly enhance neuritogenesis (p<0.05) compared to controls. Sholl 
measuring radii ranged from: 1.06-10.00mm (MiMP GM), 3.88-8.39mm (MSC GM) and 4.12-
6.22mm (controls). All images were taken at 4x, and scale bars represent 560 µm. Statistics for 
all groups were compared to controls using Games-Howell test.  
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Figure 10: Effect of Trk-receptor inhibitor drugs quantified via Sholl analysis 
Pilot study of the effect of different concentrations of cyclotraxin-B (selective TrkB receptor 
inhibitor) and GNF5837 (pan-Trk receptor inhibitor) on DRG neuritogenesis. Control (Ctrl) 
cultures included Ctrl- (basal medium; DMEM/F12, 5% FBS, ITS-X and pen-strep), Ctrl+ (basal 
medium, 10 ng/ml of each NGF, FGF and EGF) and Ctrl+/BDNF (Ctrl+, and 20 ng/ml of 
BDNF). Sholl analysis showed that medium supplemented with 1µM of cyclotraxin-B or 24 nM 
of GNF5837 significantly suppressed the number of neurites compared to Ctrl+/BDNF (p<0.05), 
and were comparable or slightly further suppressed compared to Ctrl- cultures. Number of 
neurites in cultures with 1µM of cyclotraxin-B or 24 nM of GNF5837 were suppressed 
compared to Ctrl+ cultures, but not significantly so. * denotes significant decrease of neurite 
extensions (p<0.05) of marked groups compared to Ctrl+/BDNF control cultures, determined via 
Student’s T-test.  
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Figure 11: Morphological and quantitative comparison of DRG neurite extension 
branching complexity in the presence of GNF5837 
Dorsal root ganglia (DRGs) were cultured for 5 days in medium conditioned for 48 hours by (A) 
NI-MiMPCs, (B) NI-MSC, (C) GM-MiMPCs, or (D) GM-MSCs. 24nM of pan-trk receptor 
inhibitor drug GNF5837 was added to each medium group in A-D and used to culture DRGs. 
Controls in (E) show DRGs cultured for 5 days in unconditioned basal medium. All DRG 
cultures were stained with anti-heavy neurofilament, an intermediate filament found in neurons. 
(F) Sholl analysis on DRGs show that conditioned medium (CM) collected from NI-MiMPCs 
significantly enhanced neuritogenesis over controls even in the presence of GNF5837, but DRGs 
cultures in CM from NI-MSCs did not show improvement. Sholl measurement radii ranged 
from: 1.63-8.23mm (MiMP NIM GNF), 2.83-7.50mm (MSC NIM GNF) and 3.16-5.00mm 
(controls) (G) Sholl analysis performed on images with NIH ImageJ measures the number of 
intersections, and therefore, the number of neurite extensions, which show that neuritogenesis of 
cultures in conditioned medium from GM- MiMPCs and MSCs are comparable to controls in the 
presence of 24nM of GNF5837. Sholl measurement radii ranged from: 1.87-9.36mm (MiMP GM 
GNF), 4.61-7.10mm (MSC GM GNF) and 3.16-5.00mm (controls). All DRGs were stained with 
anti-heavy neurofilament antibody and imaged. Images of conditioned medium cultures show a 
substantial increase in size and complexity of neurite outgrowth compared to controls. All 
images were taken at 4x magnification, and scale bars represent 560 µm. Statistics for all groups 
were compared to controls using Games-Howell test, and significant differences (p<0.05) are 
marked with a *. 
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Figure 12: Morphological and quantitative comparison of DRG neurite extension 
branching complexity in the presence of cucurbitacin-I 
Dorsal root ganglia (DRGs) were cultured for 5 days in medium conditioned for 48 hours by (A) 
NI-MiMPCs, (B) NI-MSC, (C) GM-MiMPCs, or (D) GM-MSCs. 60 nM of Jak/STAT inhibitor 
drug cucurbitacin-I was added to each medium group in A-D and used to culture DRGs. Controls 
in (E) show DRGs cultured for 5 days in unconditioned basal medium. All DRG cultures were 
stained with anti-heavy neurofilament, an intermediate filament found in neurons. (F-G) Sholl 
analysis performed on images via NIH ImageJ measures the number of intersections, and 
therefore, the number of neurite extensions. These showed that only neuritogenesis of DRGs 
cultured in conditioned medium from NI-MSCs showed improvement. All other CM groups 
were comparable to neuritogenesis measured in controls. Sholl measurement radii ranged from: 
2.64-4.60mm (MiMP NIM CCB), 1.77-4.70mm (MSC NIM CCB), 2.48-4.83mm (MiMP GM 
CCB), 3.09-5.02mm (MSC GM CCB) and 2.88-6.14mm (control). All DRGs were stained with 
anti-heavy neurofilament antibody and imaged. Images of conditioned medium cultures show a 
substantial increase in size and complexity of neurite outgrowth compared to controls. All 
images were taken at 4x magnification, and scale bars represent 560 µm. Statistics for all groups 
were compared to controls using Games-Howell test, and significant differences (p<0.05) are 
marked with a *. 
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3.4 DISCUSSION 
The previous chapter established that neurotrophic induction of MiMPCs enhances their ability 
to produce factors such as BDNF, IL-6 and LIF, which are able to support and enhance nerve 
regeneration. This chapter sought to create a functional bioassay to assess the utility of the 
MiMPC secretome in terms of neurite growth.  
Conditioned medium (CM) taken from NI- MiMPCs and MSCs were used to culture 
dorsal root ganglia (DRGs) on polylysine/laminin coated tissue culture plastic (TCP). Sholl 
analysis quantitatively measured neurite density, and showed that CM from both NI- and GM-
MiMPCs were able to significantly enhance neuritogenesis. By contrast, while CM from GM-
MSCs improved neurite outgrowth, the results of treatments with CM from NI-MSCs were 
comparable to controls, once again indicating that although MiMPCs are similar to MSCs in 
terms of cell markers and morphology, there are key differences that make them a distinct stem 
cell population. The difference in secretomes between MiMPCs and MSCs is particularly 
impactful as observed from the effects on neurite outgrowths in DRG cultures. While it appeared 
that under normal growth conditions, MiMPCs and MSCs provide the same benefits toward 
neurite extensions, MiMPCs and MSCs clearly alter their secretomes differently in response to a 
neuroinductive environment. 
Regardless of type, Trk receptors are responsible for neuronal survival and 
differentiation. Although cyclotraxin-B is a selective TrkB-receptor inhibitor, it was still able to 
decrease the number of neurite extensions found in DRG cultures supplemented with both NGF 
and BDNF neurotrophins. Control cultures that contained NGF but not BDNF also did not 
produce as many neurite extensions. Therefore, it is possible that BDNF plays a larger role than 
NGF when it comes to neuritogenesis. We chose GNF5837 over cyclotraxin-B as the Trk-
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receptor inhibitor drug because while there was no evident production of NGF or NT-3 
detectable in ELISAs, it was preferable to block action from all Trk receptors to avoid 
confounding results. BDNF was by far the most prominently produced neurotrophin, however, a 
multitude of other studies had shown that MSCs, at the very least, were capable of producing 
other neurotrophins (i.e., NGF). While we do not believe that either our MiMPCs or MSCs were 
producing any neurotrophins besides BDNF, there was the possibility that any low-level 
production may have degraded prior to the assays being performed. To ensure that no possible 
remnants of neurotrophins would result in activation of Trk receptors that would present with 
similar effects as BDNF and skew our results, we treated the cultures with the pan-Trk receptor 
inhibitor GNF5837. As no glial-derived neurotrophic factor (GDNF) or ciliary neurotrophic 
factor (CNTF) was detected in ELISAs, we did not pilot any studies with inhibitors against their 
receptors (CNTFR or GFRA1, respectively).  
While both our MiMPCs and MSCs are capable of producing BDNF and osteonectin 
whether or not they have gone through neurotrophic induction (Figure 3B, 6), it seems that the 
positive effects of cell-conditioned medium on DRG outgrowth can be lessened, but not 
completely abolished, with the addition of GNF5837 for all conditioned medium groups except 
NI-MiMPC. In addion, while both GM- MiMPCs and MSCs were able to enhance 
neuritogenesis, only the conditioned medium from NI-MiMPCs was able to rescue 
neuritogenesis in the presence of GNF5837. It is possible that dosage of both BDNF and 
osteonectin are important, or that osteonectin is operating through a yet unknown receptor 
pathway as a major osteonectin-mediated signaling pathway has not yet been found [32]. Taking 
all this information together, it is likely that osteonectin production by our NI-MiMPCs are 
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causing increased neuritogenesis, and therefore, higher neurite extension density compared to 
controls, even in the presence of GNF5837.  
To confirm this hypothesis, several attempts were made to reduce the amount of 
osteonectin present in CM via anti-osteonectin antibodies in the manner previously reported by 
Ma et al [32, 33]; however, the level of reduction we achieved was insignificant (data not 
shown). Our next immediate step will be to use siRNA targeting osteonectin to knock down 
expression. We will subsequently use the osteonectin-knockdown CM together with GNF5837 to 
determine if osteonectin and BDNF are enhancing DRG neuritogenesis.  
Previous studies have shown that IL-6-type cytokines, such as IL-6 and LIF, are able to 
enhance peripheral nerve regeneration by activating the Jak/STAT3 pathway [175, 176]. Our 
ELISAs showed that higher concentrations of only certain growth factors and cytokines were 
maintained both during and after the neuroinductive treatment period had concluded, including 
IL-6, but not LIF. By blocking the activation of the Jak/STAT3 pathway with the 
pharmacological inhibitor, cucurbitacin-I, we observed that our conditioned medium could not 
rescue the neurite extension complexity, and exhibited a marked decrease in length of neurite 
extension, regardless of whether the conditioned medium was taken from induced or non-
induced cells. From this, it is likely that the superior lengths of neurite extensions found in 
conditioned medium cultures are a result of these cytokines, particularly IL-6, produced by the 
cells and activating STAT3. We cannot rule out that LIF may play a role as LIF is a more potent 
cytokine than IL-6, and may be able to exert the same effects at a lower concentration [177]. 
However, the potency of LIF versus IL-6 was assessed on microvascular and endothelial cells, so 
it may still be premature to assume that LIF is having the same effect in nerve regeneration. 
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While TCP cultures can offer valuable data regarding the ability of the conditioned medium to 
promote neuritogenesis, TCP is hardly a practical medium to examine the effect of NI-MiMPC 
CM on nerve regeneration in a more clinically relevant study. In addition, obtaining true neurite 
length measurements from DRGs cultured on TCP was extremely difficult with little reliability, 
due to the highly disorganized neurite growth patterns exhibited. In our attempts to trace neurite 
lengths in these cultures, we could not accurately determine which path the neurite took, so in 
order to avoid unintentional inaccuracies in length measurements, we did not measure neurite 
elongation lengths on TCP cultures, instead examining this parameter only on aligned scaffold 
cultures. However, qualitative morphological observation clearly showed that axon extension 
lengths and sizes of DRG cultures were markedly decreased. This phenomenon could also be 
concluded simply from the fact that only a fraction of imaging tiles were needed to fully image 
the entire DRG culture at the same magnification compared to cucurbitacin-free cultures.  
We examined the length parameter only when DRGs were cultured on aligned 
nanoscaffolds. As scaffolds are commonly used in the clinic to repair nerve gaps, the electrospun 
nanoscaffolds used offer a meaningful construct in which to examine the effect of NI-MiMPC 
conditioned medium in a more physiological and clinically relevant manner. As biomaterials 
technologies advance, it may be feasible to engineer a single scaffold construct to house both 
injured nerves and stem cells. 
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4.0  NEUROTROPHICALLY INDUCED MIMPCS ENHANCE LENGTH OF 
DORSAL ROOT GANGLION NEURITE EXTENSIONS IN ELECTROSPUN 
SYNTHETIC NANOSCAFFOLD CULTURES 
4.1 INTRODUCTION 
Successful surgical treatment of peripheral nerve injury greatly depends on the mechanism of 
injury and time to treatment. The current gold standard treatment for traumatic nerve injury is the 
nerve autograft. Allograft transplants and blood vessel conduits are also favored methods in 
surgical intervention. However, these treatment methods are fraught with limitations—in the 
case of a nerve autograft, harvesting a donor nerve is invasive and damages otherwise healthy 
nerves and tissues, possibly with associated donor site morbidities, in a patient already suffering 
from the initial injury. Generally, autograft donor sites are primarily sensory nerves, which is a 
further limiting factor because it precludes proper treatment of motor nerves (tibial) or motor-
sensory (sciatic) [188]. Regeneration in mismatched nerve types may be due to differences in 
size, alignment, axonal size and distribution [189]. 
Nerve allografts and autologous blood vessel transplants can offer a solution that doesn’t 
require a secondary injury, but is limited in that the surgeon must be able to match both the 
diameter and length required in the case of blood vessels, and alignment, axonal size and 
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distribution in the case of nerve allografts. Synthetic scaffolds are an option in the clinic as well; 
however, the use of biodegradable scaffolds is not associated with a high recovery rate [190]. 
Electrospun fibrous scaffolds offer a candidate substrate for nerve repair.  Ideally, such 
scaffolds should be flexible enough to allow for movement, yet remain mechanically stiff enough 
to provide the needed support. They should be highly customizable and able to take any shape 
necessary [191] for a tensionless repair.  
Commercially available nerve conduits are hollow tubes that aim to provide structural 
support for the regenerating injured nerve. These nerve guides aim to emulate the natural 
topographical microenvironment that would typically form during the natural healing process. 
For example, synthetic scaffolds can be electrospun with aligned strands to mimic the bands of 
Büngner, formed by proliferating Schwann cells. Unlike traditional approaches, the advancement 
of biomaterials and electrospinning technology allows for fine-tuned control over various 
parameters such as material, rate of degradation, length and diameter. Poly-ε-caprolactone (PCL) 
is a biodegradable polymer that can be easily prepared and electrospun. Due to its high 
biocompatibility and slow degradation rate, it may be well suited for in vivo transplantation 
[192]. An added advantage to PCL is that it has already been approved for clinical use, which 
potentially lessens regulatory hurdles [193].  
Synthetic materials can be combined with other structural supportive materials, such as 
gels, sponges, or films, which can enhance the biochemical support capacity of the nerve guide 
and more closely imitate the function of Schwann cells and the bands of Büngner. One such 
example is gelatin. Gelatin is denatured collagen, and has been used extensively in the food, 
pharmaceutical and cosmetic industries. The fact that it is relatively inexpensive and can be 
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completely resorbed in vivo without immunogenic reactions makes it an ideal candidate for use 
in tissue engineering [194].   
Gelatin can be chemically modified for photocrosslinking by UV light in the presence of 
a photoinitiator to form a hydrogel, allowing for cell encapsulation [191]. The ability to interface 
cellular therapy with biomaterials is important for applying these scaffolds in tissue engineering. 
The incorporation of live cells into nerve scaffold constructs may provide a biochemical support 
system for the regenerating nerve in addition to physical support. However, many limitations still 
exist that prevent live cell seeding on scaffolds during fabrication (i.e., organic solvents used to 
dissolve photoinitiators are cytotoxic, and cellular DNA damage results from UV light 
crosslinking), and cells are therefore frequently seeded after scaffold fabrication, which results in 
incomplete and inefficient cell distribution, and subsequent uneven tissue regeneration [191, 
195].  
The design and materials used in our scaffold circumvents the aforementioned limitations 
of typical nerve constructs. Lin, et al developed a composite scaffold incorporating 
polycaprolactone (PCL) with methacrylated gelatin. The authors used visible light and a visible 
light-activated initiator, allowing seeded cells to survive the photocrosslinking and encapsulation 
process [191]. PCL lent structural support, while the “sacrificial” gelatin fibers served three 
purposes—when the gelatin fibers contact water, the gelatin melts and coats the PCL fibers, 
creating an adherent surface for cells in the scaffold lumen. The gelatin also acts as a glue that 
holds the PCL fibers together, allowing the creation of a multilayered PCL scaffold that has the 
strength to retain sutures. Finally, the gelatin can encapsulate cells within the scaffold wall, 
providing a biocompatible structure for cells [191].  
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Our goal is to interface this technique of photocrosslinkable gelatin with scaffolds to 
encapsulate live cells and provide both a biochemical and structural support for nerve axon 
regeneration. Extrapolating from the enhanced growth measured in the previous chapter, we 
hypothesize that MiMPCs will have a positive effect on DRG/scaffold cultures, and that with 
aligned electrospun nanoscaffolds, we will be able to quantitatively determine meaningful length 
measurements of axon extensions.  
4.2 METHODS 
4.2.1 Synthesis of Photoinitiator LAP 
The visible-light sensitive initiator lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) was 
synthesized as described by Fairbanks et al [196]. 
 
4.2.2 Preparation and photocrosslinking of methacrylated gelatin (mGelatin)  
mGelatin was prepared by reacting gelatin (type B) (Sigma-Aldrich) with methacrylic anhydride 
using our recently published protocol [191]. Photocrosslinking was initiated using the visible-
light sensitive initiator lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) [196].  
Briefly, 15 g gelatin (type B) (Sigma-Aldrich) was dissolved in 500 mL water and placed 
in a 37° C shaker at 106 rpm for 2h or until dissolved. Subsequently, 12 mL methacrylic 
anhydride (Sigma-Aldrich) was added to the solution and it was placed back into the shaker 
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overnight. The resulting solution was dialyzed against deionized water using 2000 NMWCO 
dialysis tubing (Sigma-Aldrich) for a total of 3 days with at least 10 water changes. This was 
then lyophilized to obtain a foamy solid. 
4.2.3 Fabrication of Electrospun Scaffolds  
To create electrospun scaffolds, two separate solutions of (1) 14.0% w/v PCL (80 kDa; Sigma-
Aldrich) in 2,2,2-trifluoroethanol (Sigma-Aldrich) and (2) 18% methacrylated-gelatin (mGelatin) 
in 95% 2,2,2-triflurorethanol in water. To fabricated aligned scaffolds, a custom-designed 
electrospinning device was utilized to generate a 40:60 composite scaffold consisting of 
mGelatin and PCL fibers. Two 10-mL syringes were separately filled with the PCL and 
mGelatin electrospinning solution, and they were fitted with a stainless steel 22G blunt-ended 
needle that served as a charged spinneret, and directed at a single central rotating mandrel 
(surface velocity of 10 m/s). The speed of the mandrel was sufficiently fast to align the collected 
fibers in a single direction. A flow rate of 2 mL/h was maintained with a syringe pump (Harvard 
Apparatus, Holliston, MA). A power supply (Gamma High Voltage Research, Inc., Ormond 
Beach, FL) applied a +15-20 kV potential difference between the needles and grounded mandrel 
to obtain a taylor cone for mGelatin and a +7-10 kV potential difference for PCL. Additionally, 
two aluminum shields charged to +5kV were placed perpendicular to and on either side of the 
mandrel to better direct the electrospun fibers toward the grounded mandrel. The distance 
between the mandrel and the needle was 15 cm for mGelatin fibers and 15 cm for the PCL fibers. 
The composite electrospun scaffold was generated with a final thickness of 100μm. The 
procedure was the same for creating randomly aligned scaffolds, except that the mandrel surface 
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velocity was 0.75 m/s. Scaffold alignments (random or aligned) were assessed via scanning 
electron microscopy. 
4.2.4 Preparation of medium infused scaffold and seeding of DRG 
A culture medium-mGelatin solution was prepared by combining concentrated 48hr BCM 
(concentrated using 3kD centrifugal filter tubes from Millipore [Billerica, MA], and spinning at 
3800g for 20 minutes) with 40%w/v methacrylated gelatin in Hank’s Balanced Salt Solution 
(HBSS; ThermoFisher) in a 3:1 ratio of 450 μL to 150 μL, to which 1.8 mg of photoinitiator 
LAP was added to achieve a 0.3% w/v concentration of the photoinitiator. A 3.0 x 5.5 cm sheet 
of composite scaffold consisting of either aligned or random fibers prepared as described above 
was wetted with 540 μL of the medium-mGelatin solution.  Following this, each scaffold was 
folded lengthwise (along the 5.5 cm side) into thirds. The remaining 60 μL of the medium-
mGelatin solution was then evenly applied on top of the folded random scaffold, and then the 
folded aligned scaffold was placed on top of that. The 6-layered construct was then exposed to 
visible light for 3 minutes (1.5 minutes on each side) to photopolymerize the construct. After 
construction of the completed multilayer scaffold, five cylinders of 8 mm diameter were punched 
out with a punch biopsy.   
In cell-containing scaffolds, cells were trypsinized and combined with the condensed 
culture medium-mGelatin solution and applied to scaffolds at 1 million cells per scaffold 
construct. All scaffolds (with and without cells) were prepped the same day as DRG isolations 
and kept in basal medium (DMEM-F12, 5% FBS, ITS-X and pen-strep; all from ThermoFisher) 
until needed. DRGs were seeded via the following: upon isolation from the chick embryo, DRGs 
were individually pipetted, and pipette tips were held above the scaffold and below the level of 
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medium in the well. To ensure more accurate placement on the scaffolds, DRGs were allowed to 
descend out of the pipette via gravity, rather than being actively pipetted. 
4.2.5 Live/Dead staining  
Cells were encapsulated in mGelatin and seeded onto the random fibers side of electrospun 
scaffolds. They were cultured for 24 hours prior to staining with Live/Dead assay 
(ThermoFisher). Cell viability was assessed via fluorescence microscopy images.  
4.2.6 MTS assay 
Cells were encapsulated in mGelatin and seeded onto randomly aligned electrospun fibers. All 
cells were cultured in normal growth medium. 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS [CellTiter96 Aqueous one 
solution cell proliferation assay]; ThermoFisher). MTS reagent was diluted 1:5 with FluoroBrite 
DMEM medium (ThermoFisher) and 1.25 mL was incubated with scaffold cultures for 1.5 hours 
each, at days 0 (5 hours after initial seeding), 3 and 7 timepoints. After 1.5 hours, 
MTS/FluoroBrite reagent was collected from the scaffolds and absorbencies read at 480 nm 
wavelengths.  
4.2.7 Quantitation of neurite extension lengths 
Neurite extension lengths were quantified based on images of DRGs cultured on 2-
dimensionally aligned nanofibrous poly-ε-caprolactone (PCL) scaffolds prepared by 
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electrospinning (see below). All images for scaffold cultures were taken at 10x using the inverted 
Olympus scope (IX81). Extension lengths were traced using Fiji/NIH ImageJ. Tracings were 
converted from pixel length into μm measurements using the scale of 1245 px = 800 µm. 
4.2.8 Statistical analysis 
All quantitative data are presented as means ± standard deviation, unless noted otherwise. 
Statistical differences and p-values (p<0.05) are denoted with a * and are determined by 
Levene’s and Tukey’s tests. 
4.3 RESULTS 
4.3.1 Random and aligned electrospun fibers 
Electrospun scaffolds were imaged using scanning electron microscopy (SEM) to show 
the dual surfaces of the PCL-mGelatin composite scaffold. On one side, fibers are aligned 
(Figure 13A-B) while the opposing side shows random fibers (Figure 13C-D). By combining 
aligned and randomized fibers into a single scaffold construct, we have created optimal surfaces 
for both cell adherence and growth and guidance of DRG axon extensions. SEMs of the 
composite scaffolds show thin bands of mGelatin that crosslink to form a multilayered construct 
with integrated layers of PCL (Figure 13A, C).  
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4.3.2 Medium conditioned by neurotrophically induced MiMPCs enhance dorsal root 
ganglia (DRG) neurite extension lengths 
We next determined the influence of NI-MiMPCs on DRG neurite length. This was carried out 
using embryonic chicken DRGs cultured on electrospun 2D aligned nanofibrous PCL/gelatin 
scaffolds, which afforded more consistent and reliable measurements of neurite length (Figure 
14), as the aligned fibers helped to better organize neurite outgrowth, and allowed visualization 
and more accurate measurements of axonal distance covered. However, as aligned fibers 
organized DRG axonal growth, Sholl analysis to determine neurite density was not possible, and 
not included in the results of this chapter. 
In doing so, we found that culturing DRGs in conditioned medium from any cell group 
significantly increased the length of neurite extensions compared to controls, although there was 
no difference between conditioned medium taken from any cell group (maximum length 
achieved with conditioned medium was 2,650 μm, while control lengths averaged 1,389 μm, an 
increase of 47.6%) (Figure 14 F-G). 
4.3.3 TrkB receptor does not play a part in enhancing DRG axonal extension lengths 
Again, we co-administered 24 nM of GNF5837 to determine if any factor acting through 
the Trk receptors played a role in altering length of the extensions. It has been reported that 
BDNF, acting through TrkB, is capable of activating STAT3, which is essential in axon 
extension [37]. However, the addition of the pharmacological blocker to conditioned medium did 
not result in a difference in neurite extension lengths when groups were compared to each other 
(Figure 15). All NI- and GM- conditioned medium groups significantly promoted axonal 
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extension lengths compared to controls, even with 24 nM GNF5837 supplemented. GM- 
MiMPCs and MSCs enhanced axonal length 1.93 and 1.62 times, respectively, compared to 
controls. NI- MiMPCs and MSCs similiarly enhanced axonal lengths 1.82 and 1.86 times, 
respectively, compared to controls (Figure 15 F-G).  
These results led us to conclude that BDNF was unlikely to be the sole factor produced 
by the NI- or GM-MiMPCs that contributed to neurite extension length, suggesting the action of 
another signaling pathway.  
4.3.4 IL-6 produced by MiMPCs contribute to DRG axon extension length 
In the previous chapters, PCR and ELISA data confirmed that NI-MiMPCs produced and 
maintained a high level of IL-6 compared to uninduced cells (Figures 7 and 8), so our next set of 
experiments focused on the possible involvement of IL-6 on neurite extension length of DRGs 
cultured on 2D scaffolds. In addition, we also observed an apparent decrease in axon extension 
lengths in TCP cultures, but again, was unable to accurately measure length with such 
disorganized growth. 
To test the possible involvement of IL-6 in neurite extension lengths, we chose the drug 
cucurbitacin-I to inhibit the Jak/STAT3 pathway [185]. Upon administration of cucurbitacin-I 
(60 nM) to the conditioned media, a dramatic decrease in neurite extension length of DRG 
cultures was once again observed (Figure 16). However, unlike results obtained in chapter 2, 
where axonal growth was merely truncated, DRG axon extensions were abolished on 2D scaffold 
cultures. This indicated that the actions of the Jak/STAT3 pathway and, by implication, the 
action of IL-6, was critical to neurite length, particularly in a setting of organized axon growth.  
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Since there were no observable extensions from the cucurbitacin-I treated group, these 
measurements were not included in Figure 16. As the complex, aligned topography is likely to be 
more relevant to tissue architecture in vivo, these results are consistent with an important role of 
IL-6 signaling through the Jak/STAT pathway in mediating the improvement of the length and 
complexity of neurite extensions by the MSC/MiMPC conditioned media.  
4.3.5 Cells survive the process of being encapsulated in gelatin on scaffolds 
To determine if our cells could survive the encapsulation process, we performed 
Live/Dead staining of the cells after seeding the cell/gelatin mixture onto the randomly aligned 
side of the 2D scaffolds.  The fluorescent image in Figure 17 is representative of Live/Dead 
staining of the scaffold, showing that at least 50% of the seeded cells survived after 24-hours of 
culture, determined via manual count.  
To determine if the surviving cells were sufficient for enhancing DRG axonal outgrowth, 
cells and DRGs were co-cultured on the scaffolds. Our MTS assay showed that MSCs 
proliferated between days 0, 3 and 7 in 2D scaffold cultures. MiMPCs maintained a steady level 
of metabolic activity, but did not seem to increase in number.  
4.3.6 Incorporating cells in 3D scaffolds enhances DRG neurite extension growth 
NI- or GM- cells were encapsulated in mGelatin and seeded on the random fibers side of the 
scaffold. These were co-cultured with DRGs (seeded on the aligned fibers side) on the scaffolds, 
and axon extension lengths were measured. Control DRG culture scaffolds were not seeded with 
cells. To assess if cells alone could continue producing necessary factors for nerve growth, only 
 99 
basal medium, and no conditioned medium, was used in all co-cultures. Measurements were 
significantly higher in co-cultures containing NI- or GM- MiMPCs and MSCs when compared to 
cell-free controls. Encapsulated NI-MiMPCs and NI-MSCs promoted axonal extensions that 
were 2.03 times and 2.17 times longer than controls, respectively. GM- MiMPCs and MSCs 
offered similar benefits (1.88 and 1.65 times longer than controls) (Figure 18 F-G). There was no 
significant difference in lengths of axons measured between DRGs cultured with encapsulated 
induced and non-induced cells, or between MIMPC and MSC groups (Figure 18). 
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Figure 13: Scanning electron microscopy images of polycaprolactone/mGelatin composite 
scaffolds 
SEM images of (A) Aligned PCL/mGelatin composite scaffold, (B) aligned PCL scaffold, (C) 
random PCL/mGelatin composite scaffold, and (D) random PCL scaffold. SEM of scaffolds with 
mGelatin revealed thin crosslinking structures that form a multilayered PCL scaffold. 
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Figure 14: Morphologic and quantitative comparison of DRG axonal outgrowth 
Dorsal root ganglia (DRGs) were cultured for 5 days on aligned electrospun scaffolds in medium 
conditioned for 48 hours by (A) NI-MiMPCs, (B) NI-MSC, (C) GM-MiMPCs, or (D) GM-
MSCs. Controls in (E) show DRGs cultured for 5 days in unconditioned basal medium. All 
DRGs presented in this figure are representative cultures, and were stained with anti-heavy 
neurofilament antibody and imaged via fluorescent microscopy. Morphological observation of 
DRGs in images A-D show an increase in axon extension lengths compared to controls. (F) 
Axonal extension tracings on DRGs show that conditioned medium (CM) collected from both 
NI- MiMPCs and MSCs significantly enhanced neurite extension lengths over controls. (G) The 
10 longest axonal extensions were traced in ImageJ and averaged, and show that conditioned 
medium from GM- MiMPCs and MSCs significantly enhance neurite extension outgrowth 
(p<0.05) compared to controls. All images were taken at 10x, and scale bars represent 800 µm. * 
denotes a significant difference (p<0.05) as compared to controls, determined by Tukey’s HSD 
test. 
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Figure 15: Morphologic and quantitative comparison of DRG axonal outgrowth 
supplemented with 24nM GNF5837 
DRGs were cultured for 5 days on aligned electrospun scaffolds in medium conditioned for 48 
hours by (A) NI-MiMPCs, (B) NI-MSC, (C) GM-MiMPCs, or (D) GM-MSCs. All cell 
conditioned medium was supplemented with 24 nM pan-Trk receptor inhibitor GNF5837. 
Controls in (E) show DRGs cultured for 5 days in unconditioned basal medium supplemented 
with 24 nM GNF5837. All DRGs presented in this figure are representative cultures, and were 
stained with anti-heavy neurofilament antibody and imaged via fluorescent microscopy. 
Morphological observation of DRGs in images A-D show an increase in axon extension lengths 
compared to controls. (F) Axonal extension tracings on DRGs show that conditioned medium 
(CM) collected from both NI- MiMPCs and MSCs significantly enhanced neurite extension 
lengths over controls. (G) The 10 longest axonal extensions were traced in ImageJ and averaged, 
and show that conditioned medium from GM- MiMPCs and MSCs significantly enhance neurite 
extension outgrowth (p<0.05) compared to controls. All images were taken at 10x, and scale bars 
represent 800 µm. * denotes a significant difference (p<0.05) as compared to controls, 
determined by Tukey’s HSD test. 
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Figure 16: Morphologic and quantitative comparison of DRG axonal outgrowth 
supplemented with 60 nM cucurbitacin-I 
DRGs were cultured for 5 days on aligned electrospun scaffolds in medium conditioned for 48 
hours by (A) NI-MiMPCs, (B) NI-MSC, (C) GM-MiMPCs, or (D) GM-MSCs. All cell 
conditioned medium was supplemented with 60 nM Jak/STAT inhibitor cucurbitacin-I. Controls 
in (E) show DRGs cultured for 5 days in unconditioned basal medium supplemented with 60 nM 
cucurbitacin-I. All DRGs presented in this figure are representative cultures, and were stained 
with anti-heavy neurofilament antibody and imaged via fluorescent microscopy. Morphological 
observation of DRGs in images A-E show no visible axon extensions. All images were taken at 
10x, and scale bars represent 800 µm. 
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Figure 17: Viability of mGelatin encapsulated MiMPCs seeded onto composite scaffolds as 
determined by Live-Dead and MTS assays 
MiMPCs encapsulated in mGelatin, seeded onto the random fibers side of crosslinked scaffold. 
Fluorescence microscopy image of live-dead assay shows over 50% of cells are viable after 24-
hours in culture. MTS assays, where cells were incubated with MTS reagent for 1.5 hours on 
Days 0, 3 and 7 of culture shows that MSCs proliferate after encapsulation and seeding onto 2D 
scaffolds over the course of 7 days, while MiMPCs maintain steady cell numbers in scaffold 
cultures. * denotes a significant difference (p<0.05) as compared to MiMPCs, determined by 
Tukey’s HSD test.  
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Figure 18: Morphologic and quantitative comparison of DRG axonal outgrowth when co-
cultured with cells on 2D electrospun aligned scaffold 
Dorsal root ganglia (DRGs) were co-cultured with (A) NI-MiMPCs, (B) NI-MSC, (C) GM-
MiMPCs, or (D) GM-MSCs, for 5 days on aligned electrospun scaffolds in basal medium. 
Controls in (E) show DRGs cultured for 5 days in basal medium with no cells present. All DRGs 
presented in this figure are representative cultures, and were stained with anti-heavy 
neurofilament antibody and imaged via fluorescent microscopy. Morphological observation of 
DRGs in images A-D show an increase in axon extension lengths compared to controls. (F) 
Axonal extension tracings on DRGs show that co-culture with NI- MiMPCs and MSCs 
significantly enhanced neurite extension lengths over controls. (G) The 10 longest axonal 
extensions were traced in ImageJ and averaged, and show that co-culture with GM- MiMPCs 
and MSCs significantly enhance neurite extension outgrowth (p<0.05) compared to controls. All 
images were taken at 10x, and scale bars represent 800 µm. * denotes a significant difference 
(p<0.05) as compared to controls, determined by Tukey’s HSD test. 
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4.4 DISCUSSION 
Biomaterial scaffolds provide physical support and can mimic the microenvironmental 
textures and structures found in native tissue. Living cells can be interfaced with scaffolds to 
facilitate cell coverage and regeneration of the injured area. As living tissues are complex, 
heterogeneous systems comprised of multiple cell types and tissue layers that function in tandem,  
composite scaffolds have generally yielded better outcomes than homogenous scaffolds [197, 
198]. The composite nature of our scaffolds allows for fabrication of a multilayered construct 
comprised of both aligned and random fibers. The methacrylated gelatin component of the 
scaffold allowed for crosslinking and forming a durable structure out of both types of fibers.  
Topographical cues have long been found to affect cell adhesion, growth and 
differentiation [101, 102, 104]. Multiple studies have shown the advantages of culturing DRGs 
on aligned surfaces, with data showing improved adherence and axon elongation, as well as 
increased organization among regenerated axons [31, 103, 199]. Due to the favorable 
environment that an aligned nanotopographical surface might provide, we examined the potential 
advantage of combining our conditioned medium with scaffolds for DRG cultures. However, 
studies have shown that MSCs proliferate significantly more when cultured on randomly aligned 
nanofibers when compared to aligned fibers, as well as providing structural strength and suture 
retention for in vivo use later [200]. Due to the differences in topographical preferences of the 
cells, we felt it prudent to create a scaffold that could optimally house both nerves and their 
support cells. 
Our results from the MTS assays of MSCs cultured on 2D randomly aligned nanofibers 
agree with those presented by Jahani, et al [197] as, over the course of 7 days, MSCs continued 
to proliferate in 2D scaffold cultures. However, while MiMPCs maintained a steady level of 
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metabolic activity, there was no indication of MiMPC proliferation comparable to that seen in 
MSCs (Figure 17). This suggests that encapsulation by gelatin doesn’t necessarily impede cell 
proliferation, as MSCs are capable of growing, but rather that perhaps reduced proliferation is 
specific to the MiMPC. This may imply that MiMPCs are not as robust as MSCs in terms of 
hardiness and tolerance of growth environments. However, considering the growth enhancement 
results seen in DRG cultures, we do not feel that the discrepancy in proliferative prowess 
between MiMPCs and MSCs is a critical factor. The fact that fewer MiMPCs are needed to 
achieve the same results as MSCs may be an argument in favor of using MiMPCs over MSCs, as 
this property of the MiMPC may be more economical and time-saving in the end.  
Length measurements showed enhanced DRG axon elongation from conditioned medium 
cultures compared to controls, though there were no significant differences between the various 
conditioned medium groups. When cells were seeded into the scaffold, DRGs also exhibited 
enhanced axon elongation, although again, there were no significant differences between the 
various cell types (i.e., between GM- or NI- cell groups). For practicality purposes, this finding 
may give us reason in future in vivo experiments to simply use GM- cells or conditioned medium 
taken from GM- cells. The reagents for NI- treatment can be costly, and as this parameter is 
seemingly unaffected by NI- treatment, it may be more economical to include only GM- cells in 
our studies.  
BDNF has been extensively studied, and proven to play roles in peripheral nerves relating 
to survival, growth and repair. However, DRG axon elongation was seemingly unaffected with 
the supplementation of 24 nM of GNF5837, a potent pan Trk-receptor inhibitor. As MiMPCs do 
not produce CNTF or GDNF, and the actions of other Trk-receptor mediated neurotrophin 
signaling was blocked by GNF5837, it is again plausible that BDNF either does not play as large 
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a role in axon elongation as other factors (i.e. IL-6), or that there is a compensatory or crosstalk 
mechanism between signaling pathways that can promote axon elongation even in the absence of 
any Trk-receptor mediated signaling. 
Cytokines in the IL-6 cytokine superfamily signal through the gp130 receptor to activate 
the Jak/STAT3 pathway, which has been shown to be important in the growth of neurite 
extensions and nerve regeneration [175, 201]. Our ELISA results (Figure 8) showed that NI-
MiMPCs were able to maintain production of cytokines in this family, including IL-6 and LIF, 
but not others, such as oncostatin-M and ciliary neurotrophic factor (CNTF) (data not shown). 
We postulated that these pro-inflammatory cytokines secreted into the conditioned medium from 
NI-MiMPCs could act through the Jak/STAT3 pathway to maintain improved neurite outgrowth, 
even when Trk-receptors were blocked. 
The addition of 60 nM of cucurbitacin-I inhibited axonal outgrowth from the DRG on the 
2D scaffold, whereas on TCP, cucurbitacin-I truncated, but did not completely abolish, axonal 
outgrowth. This observation suggested that the effects of cucurbitacin-I on outgrowing neurites 
could be influenced by different substrate surfaces, i.e., tissue culture plastic versus nanofibers. 
All experiments were performed with MiMPCs differentiated from human MSC-derived iPSCs, 
and the results were compared to those achieved by human MSCs. For these reasons, scaffolds 
have become an important tissue engineering tool. 
By blocking the activation of the Jak/STAT3 pathway with the pharmacological blocker, 
cucurbitacin-I, we observed that our conditioned medium could not rescue the length of neurite 
extension, regardless of whether the conditioned medium was taken from induced cells or not. 
From this, it is likely that the superior lengths of neurite extensions found in conditioned medium 
cultures are a result of these cytokines, particularly IL-6, produced by the cells, activating 
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STAT3. We cannot rule out that LIF may play a role as LIF is a more potent cytokine than IL-6, 
and may be able to exert the same effects at a lower concentration [177]. However, the potency 
of LIF versus IL-6 was assessed on microvascular and endothelial cells, so it may still be 
premature to assume that LIF is having the same effect in nerve regeneration.  
Overall, our findings show that MiMPCs can provide similar advantages as MSCs, which 
makes MiMPCs clinically applicable, and can serve as a less invasive and, more importantly, 
sustainable therapeutic method. The growth advantages associated with MiMPC cells or 
conditioned medium can be coupled with the benefits yielded by aligned scaffolds. Together, the 
two components make a renewable, biodegradable, clinically relevant system that can improve 
nerve regeneration after traumatic injury.  
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5.0  SUMMARY AND FUTURE DIRECTIONS 
Traumatic peripheral nerve injury remains a challenging field in regenerative medicine. The 
current gold standard of treatment is the nerve autograft, even though only 40-50% of patients 
exhibit functional recovery after the procedure [202]. Timely treatment is of utmost importance 
in nerve injuries, and though advances in microsurgical techniques and biomaterials have 
improved the outcome of surgical treatment, a purely surgical approach has seemingly reached 
its limit in effectiveness. Promising further advancement in peripheral nerve treatment may lie in 
delivery of supplementation of factors that can lend biochemical support. Current regenerative 
medicine research has shown significant interest in the use of stem cells, particularly induced 
pluripotent stem cells (iPSCs), in various applications, including peripheral nerve regeneration.  
 It is well established in the literature that mesenchymal stem cells (MSCs) can have 
neurotrophic effects given modulation of their chemical environment. As iPSCs are capable of 
differentiating into MSC-like cells (termed mesenchymally-induced mesenchymal progenitor 
cells [MiMPCs]), it was hypothesized that the same environmental modulation would yield 
clinically relevant neurotrophic MiMPCs. The preceding chapters attempted to optimize the use 
of MiMPCs in a neuro-regenerative capacity, and provided information on the molecular 
mechanism by which the MiMPC secretome was able to enhance axonal elongation from dorsal 
root ganglion (DRG) cultures. The most obvious and significant advantage of using MiMPCs as 
a replacement for MSCs is the fact that they are a virtually limitless source that does not require 
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invasive procedures to harvest. As MiMPCs are derived from iPSCs, rather than human 
embryonic stem cells (hESCs), their use also avoids the various ethical quandaries associated 
with the use of hESCs in research and the clinic. This, however, is counterbalanced by the fact 
that the MiMPCs are not as robust as the MSCs, and although they are capable of producing high 
levels of pertinent growth factors, they fail to thrive in neurotrophic induction medium.  
 In the second chapter, which dealt with optimization and choosing an appropriate line of 
iPSCs, it was found that iPSCs derived from mesenchymal parentage cells (MiMPCs), as 
opposed to amniotic epithelial parentage cells (AEiMPCs), yielded the more neurotrophic cell 
population after neuroinductive (NI) treatment. MiMPCs were able to produce comparatively 
higher levels of BDNF, and expressed the same mesenchymal and neuronal cell surface markers 
as MSCs and Schwann cells. As the neurogenic potential of MSCs have been repeatedly 
demonstrated, and as iPSCs retain epigenetic memory of their parental cell type, it stood to 
reason that MiMPCs, rather than AEiMPCs, may be more suited to use in nerve related studies, 
perhaps due to differences in the epigenetic nature of the original cell sources.  
Further characterization of MiMPC in terms of their likeness to neurotrophic MSCs and 
their status as a cell therapy candidate may include studying the immunogenic effects of the 
MiMPC. This may be especially important as allogenic Schwann cells have been shown to be 
immunogenic and are rejected by the host in vivo [3], as stated previously, and even though this 
work has shown that MiMPCs share many characteristics with MSCs, it cannot be denied that 
MiMPCs also exhibit some Schwann-like properties. Of course, autologous Schwann cells do not 
provoke an immune response, however the drawback lies in the fact that few cells can be 
isolated, requiring extensive ex vivo expansion, and again, requires a secondary nerve injury to 
the patient that risks scarring, neuroma formation, and functional loss. The immunomodulatory 
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properties of MSCs are well documented [203]; however, such properties of the MiMPC have 
not yet been extensively studied. Preliminary in vitro studies from our laboratory indicated that, 
similar to the MSC, MiMPCs were unable to achieve T-cell activation (data not included). 
Further work into this subject has not been done and was not included in this body of work. 
However, future studies may require a focus on immunomodulatory characteristics of the 
MiMPC as neurotrophic work continues in vivo.  
The third chapter described culturing embryonic chicken dorsal root ganglion (DRGs) 
with conditioned medium collected from NI-MiMPCs and NI-MSCs. Conditioned medium from 
all cells, both induced and uninduced, promoted neuritogenesis from the DRG. However, when a 
pan-Trk receptor inhibitor drug, GNF5837, was supplemented to block the action of BDNF, only 
conditioned medium from NI-MiMPCs still promoted increased neurite branching density. One 
possible explanation for this observation is that the NI-MiMPC is producing one or more non-
neurotrophin molecules in its secretome that can enhance nerve regeneration independently of 
the Trk-receptors. 
It should be reiterated that there were no significant differences in either neurite 
complexity or axon elongation lengths in DRG cultures between either co-culture with cells or 
cultures in conditioned medium from GM- and NI- MiMPC groups. It is noteworthy that while 
GM-MiMPCs are perfectly capable of enhancing neuritogenesis and axon elongation in 
traumatic injury, and should certainly be employed as treatments for these injuries to remain cost 
effective, the benefits NI-MiMPCs appear to convey to DRGs in the presence of Trk-receptor 
inhibitors may indicate an alternative treatment method in cases such as diabetic neuropathy, 
where injury is induced by a disease state other than exposure to traumatic injury. Growth factor 
related-tyrosine kinsases (GFR-TKs), a family of transmembrane proteins in which Trk receptors 
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are included, have been implicated as part of the disease process in diabetes [204, 205]. It may 
not be unreasonable to assume that if conditioned medium from NI-MiMPCs is robust enough to 
enhance DRG growth in the presence of a potent pan-Trk receptor inhibitor, that perhaps the 
same benefits may be conveyed in the presence of other drugs that can modulate GFR-TK 
behavior. If this is indeed the case, then it may be possible to treat both diabetic neuropathies in 
parallel with the underlying causes of the neuropathy itself. There are diabetic mouse models that 
may be of use in setting up in vivo studies for diabetic neuropathies, such as streptozotocin-
induced (STZ) diabtetes, high fat diet model, or genetic models [223], and it is also especially 
promising as a possible future direction for the clinical application of MiMPCs, as MSCs have 
seen success in alleviating diabetic neuropathies [203, 206, 207].  
As stated in the previous chapters, Taylor’s group [32, 33, 58], along with others [208, 
209], have previously reported that osteonectin is associated with axon regeneration. In order to 
determine if the MiMPC secreted osteonectin was playing a similar role, we knocked down 
osteonectin expression with siRNA to generate osteonectin-reduced conditioned medium. Our 
preliminary data from DRGs cultured with osteonectin-reduced CM suggested that while the 
presence of osteonectin may be beneficial in conditioned medium from GM- cells, it may play 
less of a role in conditioned medium from NI- cells (data not shown). Furthermore, when 
GNF5837 was supplemented to osteonectin-reduced medium, we did not observe the same 
marked reduction in neurite branching as the results of a similar experiment with Schwann cells 
that was reported by Taylor’s group. This might indicate that NI-MiMPC secretions are distinct 
enough from those of Schwann cells, and compensatory enough that they are able to encourage 
neuritogenesis even in the presence of inhibitors or absence of beneficial factors, whereas 
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Schwann cells are unable. Further study and repetition will be required to determine the effect of 
osteonectin on DRG neuritogenesis in NI- cell conditioned medium.  
It was established in chapter two that MiMPCs are capable of producing IL-6. In 
addition, there is a wealth of literature proclaiming beneficial effects of IL-6 signaling through 
the Jak/Stat pathway on nerves. From this, our prevailing hypothesis going forward was that the 
IL-6 produced by MiMPCs were exhibiting a neurotrophic effect on the DRGs, enhancing 
neuritogenesis despite the presence of pan-Trk receptor inhibitor. We tested this hypothesis in 
chapter three by supplementing conditioned medium with cucurbitacin-I, a Jak/Stat inhibitor. 
When applied to DRG cultures, we indeed observed decreased neurite outgrowth, particularly in 
length, though this parameter could not be accurately measured on tissue culture plastic. 
However, Sholl analysis showed a slight decrease in extension complexity. The fact that 
conditioned medium could not rescue neurite outgrowth in the presence of a Jak/Stat inhibitor 
indicated that molecules in the MiMPC secretome, presumably IL-6, were essential in axon 
formation and extension. 
As stated in chapter 2, multiple studies have already shown the benefits of angiogenic 
factors during nerve regeneration [69, 71, 210], and that angiogenesis and restoration of blood 
supply improves functional recovery. However, VEGF is unlikely to be affecting DRG 
outgrowth in our studies, as, unlike MSCs, MiMPCs do not produce VEGF when cultured 
outside the NI treatment medium, and DRGs were cultured only in basal conditioned medium 
collected from cells, not NI conditioned medium. As MiMPCs will remain in NI medium when 
transplanted in vivo, it is likely that MiMPCs may not be able to support angiogenesis. Therefore, 
in vivo sciatic nerve crush models may require a supply of exogenous VEGF or the MiMPCs 
may need to be transfected with VEGF-expressing plasmids in order to promote full functional 
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recovery. As tissue culture plastic was suboptimal for determining parameters other than 
complexity, aligned scaffolds were employed in DRG cultures to organize neurite outgrowth, 
and thereby provided a more accurate means of neurite length measurement. In chapter four, 
conditioned medium from all cell types and induction states enhanced neurite length over 
controls. When cells were incorporated into scaffolds, similar results were observed—both NI- 
and GM- MiMPCs and MSCs were capable of enhancing neurite extension lengths.  
Scaffold DRG cultures are inherently more clinically relevant than those on tissue culture 
plastic as surgical treatment of nerve injuries may involve the use of a scaffold as physical 
support for the native nerve. For this reason, in future in vivo studies, it may be more economical 
and efficient to incorporate conditioned medium only from GM-MiMPCs as the benefits are 
comparable between GM- and NI- cell groups.  
Fibrotic infiltrates impede axon regrowth, and can ultimately cause neuroma formation. 
While the MiMPC itself may not be capable through cytokine secretions to turn cells away, it is 
possible to prevent cellular infiltration by physical barriers (i.e. a nanofibrous scaffold into which 
cells cannot infiltrate) [212]. It remains to be seen whether our layered, PCL/gelatin composite 
scaffolds can simultaneously encapsulate MiMPCs while keeping all other cells outside of the 
lumen. We believe it is possible that immune and fibroblastic infiltrates can be kept to a 
minimum while the scaffold is intact, but once the scaffold begins to degrade, there is an 
increased chance for cells to infiltrate through cracks in the scaffold [113]. Therefore, we believe 
that the scaffold must be tailored to accommodate the length of time required for complete nerve 
regeneration. PCL degrades slowly, and may be a suitable material for this purpose, but it may 
be beneficial for future studies to further examine and optimize the materials and design of the 
scaffold to act as a semi-permeable barrier between surrounding tissues and the healing nerve.  
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The investigations presented here demonstrate the neurotrophic potential of a virtually 
limitless cell source, the MiMPC. While previous data show that MiMPCs are a more 
heterogeneous population of cells than MSCs, they are comparably neurotrophic and capable of 
supporting neurite outgrowth. Insights gained from this work indicate that further studies may 
include elucidating the neurotrophic differences in secretome between the MiMPC and MSC; 
their immunogenicity when encapsulated in scaffolds and implanted in vivo; and possible 
immunomodulatory effects of the MiMPC in comparison to MSCs. Full comprehension of the 
MiMPC secretome in terms of neurotrophism along with immunogenic or immunomodulatory 
activity may be indispensable for the development of MiMPC-based cell therapies for peripheral 
nerve injuries. 
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APPENDIX A 
VEGF PRODUCTION IN MEDIUM CONDITIONED BY MIMPCS AND MSCS 
 
Figure 19: Production of vascular endothelial growth factor (VEGF) by NI-MiMPCs  and 
MSCs, quantified via ELISA 
MiMPCs and MSCs were cultured in neurotrophic induction medium or growth medium. 
Conditioned media taken from days 7 of induction culture, and basal conditioned medium taken 
from cultures 48 hours post-induction (48hr BCM). The conditioned media assayed include those 
from MiMPCs (induced, NI-MiMPCs; un-induced, GM-MiMPCs), and from MSCs (induced, 
MI-MSCs; un-induced, GM-MSCs), as well as basal medium (controls). Medium was assayed 
for levels of VEGF via ELISA, and measured in pg/ml of VEGF produced per million cells. Both 
NI- and GM- MSCs produced VEGF. However, MiMPCs were only able to produce VEGF 
while in neurotrophic induction medium, and could not maintain VEGF secretions when cells 
were moved to basal medium.  
 118 
REPRESENTATIVE SHOLL CURVE MEASURING DRG NEURITE COMPLEXITY 
 
 
 
 
 
 
 
 
Figure 20: Representative Sholl analysis graph generated by Fiji/ImageJ measuring the 
branching complexity of neurite extensions from a DRG culture 
All DRG cultures on tissue culture plastic were imaged via fluorescent microscopy and all 
images were analyzed via the Sholl analysis plugin included in Fiji/ImageJ. The figure represents 
a typical graph generated by the Sholl analysis. The critical value (Cv), highlighted by a red 
circle, represents the peak of the graph, corresponding to the maximum number of neurite 
extensions.   
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